Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Ashleigh Koss, Media

[email protected]

Jacquie Ross, Investors

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Hospitals Pharmaceutical Health

MEDIA:

Logo
Logo

Palantir and Airbus Extend Strategic Collaboration

Palantir and Airbus Extend Strategic Collaboration

DENVER–(BUSINESS WIRE)–
Palantir Technologies (NASDAQ:PLTR) is proud to announce the extension of its collaboration with Airbus through a multi-year agreement, confirming a relationship that has driven innovation across the aerospace industry for over a decade. Under this renewed contract, Airbus will continue to rely on Palantir for Skywise, its civil aviation open data platform.

The Skywise platform enhances aircraft and equipment designs and enables greater efficiency, safety and sustainability in the production of civil aircraft across the Airbus industrial footprint. It also improves the performance of airlines’ operations by combining in-flight engineering and operational data in an analytic rich environment enabling airlines to address their main challenges.

This renewed commitment comes at a pivotal time, as the aerospace sector faces demands for innovation, agility, and competitiveness. With this renewed collaboration, Palantir will provide Airbus and its customers with continued access to cutting-edge, scalable technology while upholding the highest standards of security, confidentiality and data governance.

In alignment with Airbus’ requirements, this partnership enables seamless migration to sovereign cloud environments, providing Airbus with the flexibility to meet evolving regulatory and operational requirements.

Since 2015, Palantir’s team in France has worked alongside Airbus to deliver and evolve the Skywise platform, which supports planning, supply chain management, airlines’ operations and aircraft production. Today, 50,000+ users rely on the Skywise platform in their daily operations. Josh Harris, Executive Vice-President at Palantir, remarked: “The multi-year extension is a testament to the bold vision we share with Airbus—to reimagine the role of technology in civil aviation. Together, we will continue to deliver secure, AI-enabled capabilities with multiple LLMs that improve operational performance from manufacturing and supply chain to maintenance and flight operations.”

About Palantir

Foundational software of tomorrow. Delivered today. Additional information is available at palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the transaction details or structure, the terms of any contracts, and the expected benefits of Palantir’s software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond Palantir’s control. These risks and uncertainties include the ability to meet the unique needs of customers; the failure of Palantir’s platforms to satisfy customers or perform as desired; the frequency or severity of any software and implementation errors; Palantir’s platforms’ reliability; and customers’ ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings Palantir makes with the Securities and Exchange Commission from time to time. Except as required by law, Palantir does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Media Contact

Lisa Gordon, [email protected]

KEYWORDS: Colorado Europe United States North America France

INDUSTRY KEYWORDS: Air Technology Transport Aerospace Manufacturing Software

MEDIA:

Logo
Logo

Rambus Announces Departure of Chief Financial Officer

Rambus Announces Departure of Chief Financial Officer

SAN JOSE, Calif.–(BUSINESS WIRE)–
Rambus Inc. (NASDAQ: RMBS), a premier chip and silicon IP provider making data faster and safer, today announced that Desmond Lynch, senior vice president and chief financial officer (CFO), will resign from Rambus effective February 27, 2026, to pursue another opportunity. A formal search has commenced for a new CFO. John Allen, current vice president and chief accounting officer at Rambus, will serve as interim CFO and ensure a seamless transition until a permanent successor has been appointed.

“Des has been a valued partner in supporting the company’s continued momentum, and we thank him for his many contributions,” said Luc Seraphin, chief executive officer at Rambus. “With John serving as interim CFO, backed by our strong finance organization, we are confident in our ongoing ability to execute on our growth strategy and deliver long‑term value.”

“It has been a privilege to serve as CFO of Rambus and work alongside such a talented global team,” said Desmond Lynch. “I am proud of the financial and operational milestones Rambus achieved, and look forward to following the continued success of the company.”

Separately, Rambus is reaffirming its previously issued guidance for the first quarter of fiscal year 2026.

About Rambus Inc.

Rambus delivers industry-leading chips and silicon IP for the data center and AI infrastructure. With over three decades of advanced semiconductor experience, our products and technologies address the critical bottlenecks between memory and processing to accelerate data-intensive workloads. By enabling greater bandwidth, efficiency and security across next‑generation computing platforms, we make data faster and safer. For more information, visit rambus.com.

Forward-Looking Statements

This release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s outlook and financial guidance for the first quarter of 2026. Such forward-looking statements are based on current expectations, estimates and projections, management’s beliefs and certain assumptions made by the Company’s management. Actual results may differ materially. The Company’s business generally is subject to a number of risks which are described more fully in Rambus’ periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof.

Source: Rambus Inc.

Nicole Noutsios

Rambus Investor Relations

(510) 315-1003

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Internet Hardware Data Management Technology Semiconductor Mobile/Wireless Security

MEDIA:

Logo
Logo

United Fire Group, Inc. reports fourth quarter and full year 2025 results

Fourth quarter net income of $1.45 per diluted share
and adjusted operating income of $1.50 per diluted share

Full year net income of
$4.48
per diluted share
and adjusted operating income of
$4.60
per diluted share

Full year return on equity of
13.7%

Board of directors declares 25% increase in quarterly dividend to $0.20 per share

Fourth quarter 2025 highlights compared to fourth quarter 2024:(1)

  • Net income increased $6.9 million to $38.4 million.
  • Net investment income increased 14% to $26.4 million.
  • Combined ratio improved 2.1 points to 92.3%; composed of an underlying loss ratio of 55.4%, catastrophe loss ratio of 1.2%, no prior year reserve development, and underwriting expense ratio of 35.7%.
  • Underlying combined ratio improved 1.7 points to 91.1%.
  • Net written premium(2) increased 11% to $309.7 million.

Full year 2025 highlights compared to full year 2024:(1)

  • Net income increased $56.2 million to $118.2 million.
  • Net investment income increased 19% to $97.5 million.
  • Combined ratio improved 4.4 points to 94.8%; composed of an underlying loss ratio of 56.3%, catastrophe loss ratio of 3.2%, favorable prior year reserve development of 0.4% and underwriting expense ratio of 35.7%.
  • Underlying combined ratio improved 1.8 points to 92.0%.
  • Net written premium(2) increased 9% to $1.3 billion.
  • Book value per share increased $6.08 to $36.88 as of December 31, 2025, compared to December 31, 2024.
  • Adjusted book value per share increased $4.23 to $37.87 as of December 31, 2025, compared to December 31, 2024.

CEDAR RAPIDS, Iowa, Feb. 10, 2026 (GLOBE NEWSWIRE) — United Fire Group, Inc. (UFG) (Nasdaq: UFCS) today reported financial results for the fourth quarter ended December 31, 2025, with net income increasing $6.9 million over the prior year to $38.4 million ($1.45 per diluted share) and adjusted operating income increasing $7.2 million over the prior year to $39.7 million ($1.50 per diluted share).

In the fourth quarter, net written premium grew 11% with retention and new business above the prior year period and an average renewal premium increase of 6.3%. The fourth quarter combined ratio improved 2.1 points to 92.3% with improved underlying loss ratio, expense ratio and catastrophe losses, while prior year reserve development remained neutral overall. Net investment income of $26.4 million increased 14% from the prior year period.

For the full year, net written premium grew 9% with retention and new business strongly above prior year and an average renewal premium increase of 8.7%. The annual combined ratio of 94.8% improved 4.4 points from prior year with improvement across all components. Net investment income of $97.5 million increased 19% from prior year.

“UFG produced excellent results in the fourth quarter, providing a strong close to a year of outstanding achievements,” said President and CEO Kevin Leidwinger. “Through the efforts of our exceptional team, UFG achieved record levels of gross written premium, net written premium and new business production in 2025 while delivering the best annual underwriting profit, investment income and return on equity in a decade or longer.

“These milestones reflect the actions taken over the past several years to transform the company and significantly improve its operating performance. Our deepened expertise, evolved capabilities, enhanced actuarial insights and improved alignment with distribution partners have enabled us to more broadly serve our customers, which we believe positions UFG for continued profitable growth as a disciplined, solution-oriented underwriting company.

“As we embark on our 80th year in business in 2026, UFG is well poised to navigate the complexities of an evolving market and will remain focused on the strategic execution of our business plan. With confidence in our future financial performance and an enduring commitment to creating long-term value for our shareholders, I am pleased to announce that the board of directors has declared a 25% increase in our quarterly cash dividend from $0.16 per share to $0.20 per share.”

Earnings call access information

An earnings call will be held at 9:00 a.m. CT on Wednesday, February 11, 2026, to allow securities analysts, shareholders and other interested parties the opportunity to hear management discuss the company’s fourth quarter of 2025 results.

Teleconference: Dial-in information for the call is toll-free 1-844-492-3723 (international 1-412-542-4184). The event will be archived and available for digital replay through February 25, 2026. The replay access information is toll-free 1-855-669-9658 (international 1-412-317-0088); conference ID no. 4788997.

Webcast: An audio webcast of the teleconference can be accessed at the company’s investor relations page at https://ir.ufginsurance.com/events-and-presentations/ or https://event.choruscall.com/mediaframe/webcast.html?webcastid=J7pQ65cr. The archived audio webcast will be available for one year.

Transcript: A transcript of the teleconference will be available on the company’s website soon after the completion of the teleconference.

(1) Underlying loss ratio, underlying combined ratio and adjusted book value per share are non-GAAP financial measures. See Definitions of non-GAAP information and reconciliations to comparable GAAP measures for additional information.

(2) Net written premium is a performance measure reflecting the amount charged for insurance policy contracts issued and recognized on an annualized basis at the effective date of the policy. See Certain performance measures for additional information.

Consolidated financial highlights:

Consolidated financial highlights

(1)
(Unaudited)   Three months ended
December 31,
  Twelve months ended
December 31,
(In thousands, except ratios and per share data)     2025       2024       2025       2024  
Net earned premium   $ 341,052     $ 308,137     $ 1,292,696     $ 1,176,750  
Net written premium     309,747       278,529       1,346,219       1,231,470  
                 
Combined ratio:                
Net loss ratio     56.6 %     57.3 %     59.1 %     63.3 %
Underwriting expense ratio     35.7 %     37.1 %     35.7 %     35.9 %
Combined ratio     92.3 %     94.4 %     94.8 %     99.2 %
                 
Additional ratios:                
Net loss ratio     56.6 %     57.3 %     59.1 %     63.3 %
Catastrophes     1.2 %     1.6 %     3.2 %     5.4 %
Reserve development (favorable) unfavorable     %     %     (0.4 )
%
    %
Underlying loss ratio (non-GAAP)     55.4 %     55.7 %     56.3 %     57.9 %
Underwriting expense ratio     35.7 %     37.1 %     35.7 %     35.9 %
Underlying combined ratio (non-GAAP)     91.1 %     92.8 %     92.0 %     93.8 %
                 
Net investment income   $ 26,415     $ 23,156     $ 97,538     $ 81,986  
Net investment gains (losses)     (1,661 )     (1,318 )     (3,822 )     (5,429 )
Net income (loss)     38,354       31,442       118,191       61,957  
Adjusted operating income (loss)     39,666       32,483       121,210       66,246  
                 
Net income (loss) per diluted share   $ 1.45     $ 1.21     $ 4.48     $ 2.39  
Adjusted operating income (loss) per diluted share     1.50       1.25       4.60       2.56  
                 
Return on equity(2)             13.7 %     8.2 %


(1) Underlying loss ratio, underlying combined ratio and adjusted operating income (loss) are non-GAAP financial measures. SeeDefinitions of non-GAAP information and reconciliations to comparable GAAP measuresfor additional information.

(2) Return on equity is calculated by dividing annualized net income by average stockholders’ equity, which is calculated using a simple average of the beginning and ending balances for the period.


Fourth quarter 2025 results:


(All comparisons vs.
fourth
quarter 2024, unless noted otherwise)

Net written premium and net earned premium each increased by 11%. Core commercial lines net written premium increased 9% supported by improved retention, increased pricing and higher new business. Overall, average renewal premiums increased 6.3% with rates increasing 4.8% and exposure changes of 1.5%. Excluding the workers’ compensation line of business, the overall average increase in renewal premiums was 7.0%, with 5.7% from rate increases and 1.3% from exposure changes.

The fourth quarter combined ratio improved 2.1 points to 92.3% compared to 94.4% in the prior year quarter, driven by the following:

  • The underlying loss ratio improved 0.3 points to 55.4%, reflecting sustained lower frequency and earned rate achievement as well as favorable large loss experience compared to historical levels.
  • Catastrophe losses improved 0.4 points to 1.2%, below both the five-year and 10-year historical averages.
  • Prior year reserve development, excluding catastrophe losses, was neutral for the fourth quarter of 2025.
  • The underwriting expense ratio of 35.7% improved 1.4 points mainly driven by continued focus on disciplined expense management and business growth.


Full year 2025 results:


(All comparisons vs. full year 2024, unless noted otherwise)

Net written premium and net earned premium increased by 9% and 10%, respectively. Core commercial lines net written premium increased 14% supported by improved retention, increased pricing and higher new business. Overall, average renewal premiums increased 8.7% with rates increasing 7.0% and exposure changes of 1.6%. Excluding the workers’ compensation line of business, the overall average increase in renewal premiums was 9.6%, with 8.0% from rate increases and 1.5% from exposure changes.

The full year combined ratio improved 4.4 points to 94.8% compared to 99.2% in the prior full year, driven by the following:

  • The underlying loss ratio improved 1.6 points to 56.3%, reflecting sustained lower frequency and earned rate achievement as well as favorable large loss experience compared to historical levels.
  • Catastrophe losses improved 2.2 points to 3.2%, below both the five-year and 10-year historical averages.
  • Prior year reserve development, excluding catastrophe losses, was favorable at 0.4% for the full year 2025, compared to neutral prior year reserve development in the full year 2024.
  • The underwriting expense ratio of 35.7% improved 0.2 points mainly driven by continued focus on disciplined expense management and business growth.

Investment Results


Fourth quarter 2025 results:


(All comparisons vs.
fourth
quarter 2024, unless noted otherwise)

Net investment income was $26.4 million for the fourth quarter of 2025, an increase of $3.3 million or 14.1%. Income from the fixed maturity portfolio increased by $3.5 million as a result of portfolio growth and reinvestment at higher yields. Income on other long-term investments increased $0.2 million to $2.4 million on increased valuations.


Full year 2025 results:


(All comparisons vs. full year 2024, unless noted otherwise)

Net investment income was $97.5 million for the full year 2025, an increase of $15.6 million or 19.0%. Income from the fixed maturity portfolio increased by $17.9 million as a result of portfolio management actions and portfolio growth. This was partially offset by decreased income on other long-term investments of $6.9 million compared to $7.9 million in the full year 2024, due to strong performance in certain sectors during 2024.

Investment results
(Unaudited)   Three months ended
December 31,
  Twelve months ended
December 31,
(In thousands, except average yields)     2025       2024       2025       2024  
Investment income:                
Interest on fixed maturities   $ 23,342     $ 19,877     $ 87,642     $ 69,703  
Dividends on equity securities                       341  
Income (loss) on other long-term investments     2,360       2,150       6,944       7,939  
Other     3,708       3,692       15,123       14,951  
Total investment income   $ 29,410     $ 25,719     $ 109,709     $ 92,934  
Less investment expenses     2,995       2,563       12,171       10,948  
Net investment income   $ 26,415     $ 23,156     $ 97,538     $ 81,986  
                 
Average yields on fixed income securities pre-tax(1)     4.38 %     4.15 %     4.29 %     3.73 %


(1) Fixed income securities yield excluding net unrealized investment gains/losses and expenses.

Balance sheet

    December 31, 2025
  December 31, 2024
(In thousands, except per share data)  
(unaudited)
   
Invested assets   $ 2,464,687     $ 2,093,094  
Cash     156,332       200,949  
Total assets     3,840,789       3,488,469  
Losses and loss settlement expenses     1,924,826       1,796,782  
Total liabilities     2,899,619       2,706,938  
Net unrealized investment gains (losses), after-tax     (25,268 )     (72,241 )
Total stockholders’ equity     941,170       781,531  
         
Book value per share   $ 36.88     $ 30.80  
Adjusted book value per share(1)     37.87       33.64  


(1) Adjusted book value per share is a non-GAAP financial measure. SeeDefinitions of non-GAAP information and reconciliations to comparable GAAP measuresfor additional information.

The company’s book value per share was $36.88, an increase of $6.08 per share, or 19.7%, from December 31, 2024. This increase is primarily related to an increase in net income and a decrease in unrealized investment losses on fixed maturity securities, partially offset with shareholder dividends during the twelve-month period ended December 31, 2025.

Capital management

During the fourth quarter of 2025, the company declared and paid a $0.16 per share cash dividend to shareholders of record as of December 5, 2025.

On February 9, 2026, the company’s board of directors declared a common stock quarterly cash dividend of $0.20 per share. The dividend will be payable March 10, 2026, to shareholders of record as of February 24, 2026.

About UFG

Founded in 1946 as United Fire & Casualty Company, UFG, through its insurance company subsidiaries, is engaged in the business of writing property and casualty insurance. The company is licensed as a property and casualty insurer in 50 states and the District of Columbia, and is represented by approximately 850 independent agencies. AM Best assigns a rating of “A-” (Excellent) for members of the United Fire & Casualty Group. For more information about UFG, visit www.ufginsurance.com.

Contact:

Investor relations

Email: [email protected]

Media inquiries

Email: [email protected]

Disclosure of forward-looking statements

This release may contain forward-looking statements about our operations, anticipated performance and other similar matters. The Private Securities Litigation Reform Act of 1995 provides a safe harbor under the Securities Act of 1933 and the Securities Exchange Act of 1934 for forward-looking statements. The forward-looking statements are not historical facts and involve risks and uncertainties that could cause actual results to differ from those expected and/or projected. Such forward-looking statements are based on current expectations, estimates, forecasts and projections about the company, the industry in which we operate, and beliefs and assumptions made by management. Words such as “expect(s),” “anticipate(s),” “intend(s),” “plan(s),” “believe(s),” “continue(s),” “seek(s),” “estimate(s),” “goal(s),” “remain(s) optimistic,” “target(s),” “forecast(s),” “project(s),” “predict(s),” “should,” “could,” “may,” “will,” “might,” “hope,” “can” and other words and terms of similar meaning or expression in connection with a discussion of future operations, financial performance or financial condition, are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Information concerning factors that could cause actual outcomes and results to differ materially from those expressed in the forward-looking statements is contained in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024 (“2024 Annual Report”), filed with the Securities and Exchange Commission (“SEC”) on February 26, 2025. The risks identified in our 2024 Annual Report and in our other SEC filings are representative of the risks, uncertainties, and assumptions that could cause actual outcomes and results to differ materially from what is expressed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release or as of the date they are made. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. In addition, future dividend payments are within the discretion of our Board of Directors and will depend on numerous factors, including our financial condition, our capital requirements and other factors that our Board of Directors considers relevant.

Definitions of non-GAAP information and reconciliations to comparable GAAP measures

The company prepares its financial statements in conformity with generally accepted accounting principles (GAAP) in the United States of America. Management uses certain non-GAAP financial measures to evaluate its operations and profitability. Management also believes that disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance. Non-GAAP financial measures disclosed in this report include: adjusted operating income, underlying loss ratio, underlying combined ratio, and adjusted book value per share. The company has provided the following definitions and reconciliations of the non-GAAP financial measures:

Adjusted operating income: Adjusted operating income is calculated by excluding net investment gains and losses, after applicable federal and state income taxes from net income (loss). Management believes adjusted operating income is a meaningful measure for evaluating insurance company performance and a useful supplement to GAAP information because it better represents the normal, ongoing performance of our business. Investors and equity analysts who invest in and report on the insurance industry and the company generally focus on this metric in their analyses.

Net income reconciliation
(Unaudited)   Three months ended
December 31,
  Twelve months ended
December 31,
(In thousands, except per share data)     2025       2024       2025       2024  
Income statement data                
Net income (loss)   $ 38,354     $ 31,442     $ 118,191     $ 61,957  
Less: after-tax net investment gains (losses)     (1,312 )     (1,041 )     (3,019 )     (4,289 )
Adjusted operating income (loss)   $ 39,666     $ 32,483     $ 121,210     $ 66,246  
Diluted earnings per share data                
Net income (loss)   $ 1.45     $ 1.21     $ 4.48     $ 2.39  
Less: after-tax net investment gains (losses)     (0.05 )     (0.04 )     (0.12 )     (0.17 )
Adjusted operating income (loss)   $ 1.50     $ 1.25     $ 4.60     $ 2.56  



Underlying loss ratio and underlying combined ratio:
Underlying loss ratio represents the net loss ratio less the impacts of catastrophes and non-catastrophe prior year reserve development. The underlying combined ratio represents the combined ratio less the impacts of catastrophes and non-catastrophe prior year reserve development. The company believes that the underlying loss ratio and underlying combined ratio are meaningful measures to understand the underlying trends in the core business in the current accident year, removing the volatility of prior year impacts and catastrophes. Management believes separate discussions on catastrophe losses and prior year reserve development are important to understanding how the company is managing catastrophe risk and identifying developments in longer-tailed business.

Prior year reserve development is the increase (unfavorable) or decrease (favorable) in incurred loss and loss adjustment expense at the valuation dates for losses which occurred in previous calendar years. This measure excludes development on catastrophe losses.

Catastrophe losses is an operational measure which utilizes the designations of the Insurance Services Office (“ISO”) and is reported with losses and loss adjustment expense amounts net of reinsurance recoverables, unless specified otherwise. In addition to ISO catastrophes, we also include as catastrophes those events, which may include U.S. or international losses, that we believe are, or will be, material to our operations, either in amount or in number of claims made. Catastrophes are not predictable and are unique in terms of timing and financial impact. While management estimates catastrophe losses as incurred, due to the inherently unique nature of catastrophe losses, the impact in a reporting period is inclusive of catastrophes that occurred in the reporting period, as well as development on catastrophes that have occurred in prior periods.

Adjusted book value per share: Adjusted book value per share is calculated by dividing shareholders’ equity, excluding net unrealized investment gains and losses, net of tax, by the number of common shares outstanding. Management believes adjusted book value per share is a meaningful measure for evaluating the company’s net worth that is primarily attributable to our business operations, because it removes the effect of changing prices on invested assets that can fluctuate from period to period. Book value per share is the most directly comparable GAAP measure.

Book value per share reconciliation
(Unaudited)    
(In thousands, except per share data)   December 31, 2025   December 31, 2024
Shareholders’ equity   $ 941,170     $ 781,531  
Less: Net unrealized investment gains (losses), net of tax     (25,268 )     (72,241 )
Shareholders’ equity, excluding net unrealized investment gains (losses), net of tax   $ 966,438     $ 853,772  
         
Common shares outstanding (basic)     25,522       25,378  
Book value per share   $ 36.88     $ 30.80  
Adjusted book value per share     37.87       33.64  



Certain performance measures

The company uses the following measure to evaluate its financial performance. Management believes a discussion of this measure provides financial statement users with a better understanding of the company’s results of operations. The company has provided the following definition:

Net written premium: Net written premium is frequently used by industry analysts and other recognized reporting sources to facilitate comparisons of the performance of insurance companies. Net written premium is the amount charged for insurance policy contracts issued and recognized on an annualized basis at the effective date of the policy. Management believes net written premium is a meaningful measure for evaluating insurance company sales performance and geographical expansion efforts. Net written premium for an insurance company consists of direct premiums written and premiums assumed, less premiums ceded. Net earned premium is calculated on a pro-rata basis over the terms of the respective policies. Unearned premium reserves are established for the portion of written premium applicable to the unexpired terms of the insurance policies in force. The difference between net earned premium and net written premium is the change in unearned premium and the change in prepaid reinsurance premiums.

Supplemental tables

Income statement
(Unaudited)   Three months ended
December 31,
  Twelve months ended
December 31,
(In thousands)     2025       2024       2025       2024  
Revenues                
Net earned premium   $ 341,052     $ 308,137     $ 1,292,696     $ 1,176,750  
Net investment income     26,415       23,156       97,538       81,986  
Net investment gains (losses)     (1,661 )     (1,318 )     (3,822 )     (5,429 )
Other income (loss)           3,200              
Total revenues   $ 365,806     $ 333,175     $ 1,386,412     $ 1,253,307  
                 
Benefits, losses and expenses                
Losses and loss settlement expenses   $ 192,794     $ 176,486     $ 764,402     $ 744,605  
Amortization of deferred policy acquisition costs     82,043       76,834       315,323       281,338  
Other underwriting expenses     39,592       37,410       146,609       140,942  
Interest expense     3,182       2,481       11,267       7,281  
Other non-underwriting expenses     (9 )     419       875       2,107  
Total benefits, losses and expenses   $ 317,602     $ 293,630     $ 1,238,476     $ 1,176,273  
                 
Income (loss) before income taxes   $ 48,204     $ 39,545     $ 147,936     $ 77,034  
Income tax expense (benefit)     9,850       8,103       29,745       15,077  
Net income (loss)   $ 38,354     $ 31,442     $ 118,191     $ 61,957  

Net written premium by line of business


(Unaudited)   Three months ended
December 31,
  Twelve months ended
December 31,
(In thousands)     2025       2024       2025       2024  
Net written premium

(1)
                       
Commercial lines:                        
Other liability(2)   $ 105,964     $ 90,508     $ 420,016     $ 369,454  
Fire and allied lines(3)     59,607       54,203       265,529       253,796  
Automobile     65,816       53,776       305,284       258,257  
Workers’ compensation     16,129       14,011       75,490       61,838  
Surety(4)     15,629       10,013       63,432       52,524  
Miscellaneous     301       3,201       4,844       13,086  
Total commercial lines   $ 263,446     $ 225,712     $ 1,134,595     $ 1,008,955  
                         
Personal lines:                        
Fire and allied lines(5)   $ 613     $ 3,804     $ 15,917     $ 14,201  
Automobile     51       764       516       2,449  
Miscellaneous                       5  
Total personal lines   $ 664     $ 4,568     $ 16,433     $ 16,655  
Assumed reinsurance(6)     45,637       48,249       195,191       205,860  
Total   $ 309,747     $ 278,529     $ 1,346,219     $ 1,231,470  


(1) Net written premium is a performance measure reflecting the amount charged for insurance policy contracts issued and recognized on an annualized basis at the effective date of the policy. See Certain performance measures for additional information.

(2) Commercial lines “Other liability” is business insurance covering bodily injury and property damage arising from general business operations, accidents on the insured’s premises and products manufactured or sold.

(3) Commercial lines “Fire and allied lines” includes fire, allied lines, commercial multiple peril and inland marine.

(4) Commercial lines “Surety” previously referred to as “Fidelity and surety.”

(5) Personal lines “Fire and allied lines” includes fire, allied lines, homeowners and inland marine.

(6) Assumed reinsurance includes Funds at Lloyd’s.

Net earned premium, net losses and loss settlement expenses and net loss ratio by line of business
Three months ended December 31,     2025       2024  
          Net losses             Net losses    
          and loss             and loss    
    Net


  settlement   Net   Net   settlement   Net
(Unaudited)   earned


  expenses   loss   earned   expenses   loss
(In thousands, except ratios)   premium


  incurred   ratio   premium   incurred   ratio
Commercial lines                            
Other liability   $ 105,357     $ 76,161     72.3 %   $ 91,016     $ 82,052     90.2 %
Fire and allied lines     65,992       21,372     32.4       62,019       16,515     26.6  
Automobile     79,798       41,170     51.6       63,276       28,893     45.7  
Workers’ compensation     17,967       12,684     70.6       14,914       8,233     55.2  
Surety     15,992       10,150     63.5       15,537       (179 )   (1.2 )
Miscellaneous     1,310       492     37.6       3,223       611     19.0  
Total commercial lines   $ 286,416     $ 162,029     56.6 %   $ 249,985     $ 136,125     54.5 %
                             
Personal lines                            
Fire and allied lines   $ 4,814     $ 1,920     39.9 %   $ 3,814     $ 5,110     134.0 %
Automobile     230       144     62.6 %     639       424     66.4 %
Miscellaneous           (7 )   NM     2       4     NM
Total personal lines   $ 5,044     $ 2,057     40.8 %   $ 4,455     $ 5,538     124.3 %
Assumed reinsurance     49,592       28,708     57.9       53,697       34,823     64.9  
Total   $ 341,052     $ 192,794     56.6 %   $ 308,137     $ 176,486     57.3 %


NM = Not meaningful

Net earned premium, net losses and loss settlement expenses and net loss ratio by line of business
Twelve months ended December 31,     2025       2024  
          Net losses             Net losses    
          and loss             and loss    
    Net


  settlement   Net   Net   settlement   Net
(Unaudited)   earned


  expenses   loss   earned   expenses   loss
(In thousands, except ratios)   premiums


  incurred   ratio   premiums   incurred   ratio
Commercial lines                              
Other liability   $ 389,154     $ 283,599     72.9 %   $ 343,027     $ 283,034     82.5 %
Fire and allied lines     259,005       109,972     42.5       252,142       125,807     49.9  
Automobile     287,996       166,028     57.6       239,964       138,517     57.7  
Workers’ compensation     65,040       43,291     66.6       54,815       37,524     68.5  
Surety     64,096       24,522     38.3       60,285       14,812     24.6  
Miscellaneous     10,004       5,614     56.1       9,802       5,742     58.6  
Total commercial lines   $ 1,075,295     $ 633,026     58.9 %   $ 960,035     $ 605,436     63.1 %
                               
Personal lines                              
Fire and allied lines   $ 14,690     $ 6,146     41.8 %   $ 14,237     $ 8,325     58.5 %
Automobile     1,752       1,116     63.7 %     1,214       732     60.3 %
Miscellaneous     2       (54 )   NM     10       197     NM
Total personal lines   $ 16,444     $ 7,208     43.8 %   $ 15,461     $ 9,254     59.9 %
Assumed reinsurance     200,957       124,168     61.8       201,254       129,915     64.6  
Total   $ 1,292,696     $ 764,402     59.1 %   $ 1,176,750     $ 744,605     63.3 %


NM = Not meaningful



Advanced Energy Reports Fourth Quarter and Full Year 2025 Results

Advanced Energy Reports Fourth Quarter and Full Year 2025 Results

  • Q4 revenue was $489 million, at the high end of guidance
  • Q4 GAAP EPS from continuing operations was $1.31; non-GAAP EPS was $1.94, both towards the high end of guidance
  • 2025 revenue grew 21% to $1.80 billion
  • Data Center Computing revenue grew 107% to a record level
  • 2025 GAAP EPS from continuing operations was $3.87; non-GAAP EPS was $6.41, up 73% year-over-year
  • Cash flow from continuing operations was a record $235 million

DENVER–(BUSINESS WIRE)–
Advanced Energy Industries, Inc. (Nasdaq: AEIS), a global leader in highly engineered, precision power conversion, measurement, and control solutions, announced financial results for the fourth quarter and year ended December 31, 2025.

“Fourth quarter results exceeded our guidance, primarily driven by increased demand in the semiconductor market,” said Steve Kelley, president and CEO of Advanced Energy. “In 2025, we delivered strong revenue growth and meaningfully improved gross and operating margins, reflecting the benefits of our diversification strategy and execution of our operational initiatives. Entering 2026, we believe demand across our markets is strengthening, and customer adoption of our next-generation platforms will drive market share gains.”

Quarter Results

Revenue was $489 million in the fourth quarter of 2025, compared with $463 million in the third quarter of 2025 and $415 million in the fourth quarter of 2024.

GAAP net income from continuing operations was $53 million or $1.31 per diluted share in the quarter, compared with $46 million or $1.21 per diluted share in the prior quarter, and $49 million or $1.29 per diluted share a year ago. GAAP net income in the fourth quarter of 2024 included a one-time, net tax benefit of $15 million as a result of an intercompany transfer of assets as part of the company streamlining its legal entity structure.

Non-GAAP net income was $75 million or $1.94 per diluted share in the fourth quarter of 2025. This compares with $66 million or $1.74 per diluted share in the third quarter of 2025, and $49 million or $1.30 per diluted share in the fourth quarter of 2024.

During the fourth quarter of 2025, Advanced Energy generated $80 million in cash flow from continuing operations during the quarter, repurchased $6.7 million of common stock, and paid $4.0 million in quarterly dividends.

Full Year 2025 Results

2025 revenue was $1.80 billion, a 21% increase from $1.48 billion in 2024.

GAAP net income from continuing operations was $149 million or $3.87 per diluted share in 2025, compared with $56 million or $1.49 per diluted share in 2024.

GAAP net income in 2024 included a one-time, net tax benefit of $15 million as a result of an intercompany transfer of assets as part of the company streamlining its legal entity structure and a $30 million restructuring charge as part of our previously announced manufacturing consolidation.

Non-GAAP net income was $245 million or $6.41 per diluted share in 2025, compared with $140 million or $3.71 per diluted share in 2024

In 2025, the company generated $235 million in cash flow from operating activities from continuing operations, repurchased $30 million of common stock at an average price of $96.79, and paid $15.6 million in dividends. At year-end, outstanding debt was $568 million, representing the 2028 convertible notes, net of unamortized issuance costs. Cash and equivalents at year-end were $791 million.

A reconciliation of GAAP and non-GAAP measures is provided in the tables below.

First Quarter 2026 Guidance

Based on the Company’s current view, beliefs, and assumptions, guidance is within the following ranges:

 

 

 

 

 

 

 

 

Q1 2026

Revenue

$500 million +/- $20 million

GAAP EPS from continuing operations

$1.44 +/- $0.25

Non-GAAP EPS

$1.94 +/- $0.25

Conference Call

Management will host a conference call today, February 10, 2025, at 4:30 p.m. Eastern Time to discuss the fourth quarter financial results. To participate in the live earnings conference call, please dial 877-407-0890 approximately ten minutes prior to the start of the meeting and an operator will connect you. International participants can dial +1-201-389-0918. A webcast will also be available on our investor web page at ir.advancedenergy.com in the Events & Presentations section. The archived webcast will be available approximately two hours following the end of the live event.

About Advanced Energy

Advanced Energy Industries, Inc. (Nasdaq: AEIS) is a global leader in the design and manufacture of highly engineered, precision power conversion, measurement and control solutions for mission-critical applications and processes. Advanced Energy’s power solutions enable customer innovation in complex applications for a wide range of industries including semiconductor equipment, industrial production, medical and life sciences, data center computing, networking, and telecommunications. With engineering know-how and responsive service and support for customers around the globe, the Company builds collaborative partnerships to meet technology advances, propels growth of its customers, and innovates the future of power. Advanced Energy has devoted four decades to perfecting power. It is headquartered in Denver, Colorado, USA. For more information, visit www.advancedenergy.com.

Advanced Energy | Precision. Power. Performance. Trust.

Non-GAAP Measures

This release includes measures, such as non-GAAP net income, non-GAAP operating income, and non-GAAP earnings per share (“EPS”) that are not prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Management uses non-GAAP net income and non-GAAP EPS to evaluate business performance without the impacts of certain non-cash charges and other charges which are not part of our usual operations. We use these non-GAAP measures to assess performance against business objectives and make business decisions, including developing budgets and forecasting future periods. In addition, management’s incentive plans include certain of these non-GAAP measures as criteria for achievements. These non-GAAP measures are not prepared in accordance with U.S. GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies. However, we believe these non-GAAP measures provide additional information that enables readers to evaluate our business from the perspective of management. The presentation of this additional information should not be considered a substitute for results prepared in accordance with U.S. GAAP.

The non-GAAP results presented below exclude the impact of non-cash related charges, such as stock-based compensation, amortization of intangible assets, and long-term unrealized foreign exchange gains and losses. In addition, we exclude discontinued operations and other items such as acquisition-related costs, facility, infrastructure, and other transition costs, and restructuring expenses, as they are not indicative of future performance. The tax effect of our non-GAAP adjustments represents the anticipated annual tax rate applied to each non-GAAP adjustment after consideration of their respective book and tax treatments. Non-GAAP results also exclude non-recurring discrete tax expenses or benefits. Finally, non-GAAP diluted weighted-average common shares are adjusted to reflect the dilutive impact of our convertible note based on the higher note hedge strike price instead of the initial conversion price.

Forward-Looking Statements

This press release and statements we make on the above announced conference call contain, in addition to historical information, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release or the conference call that are not historical information are forward-looking statements. For example, statements relating to our beliefs, expectations, and plans are forward-looking statements, as are statements that certain actions, conditions, or circumstances will continue. The inclusion of words such as “anticipate,” “expect,” “estimate,” “can,” “may,” “might,” “continue,” “enables,” “plan,” “intend,” “should,” “could,” “would,” “likely,” “potential,” or “believe,” and similar expressions and the negative versions thereof indicate forward-looking statements; however, not all forward-looking statements may contain such words or expressions. These forward-looking statements are based upon information available as of the date of this press release and management’s current estimates, forecasts, and assumptions. Although we believe that our expectations reflected in or suggested by these forward-looking statements are reasonable, we may not achieve the results, performance, plans, or objectives expressed or implied by such forward-looking statements. Forward-looking statements involve risks and uncertainties, which are difficult to predict and many of which are beyond our control.

Risks and uncertainties to which our forward-looking statements are subject include, but are not limited to: volatility and business fluctuations in the industries in which we compete; our ability to achieve design wins with new and existing customers; our ability to accurately forecast and meet customer demand; risks related to global economic conditions, such as the impact of tariffs and export regulations, escalating global conflicts on macroeconomic conditions, economic uncertainty, market volatility, rising interest rates, inflation, lack of growth in our markets or recession; customer price sensitivity; the U.S. Dollar’s change in value against its major peers; concentration of our customer base; risks associated with potential breach of our information security measures, either external breach or internal data theft; difficulties with the implementation of our enterprise resource planning and other enterprise-wide information technology system applications; our loss of or inability to attract and retain key personnel; risks associated with our manufacturing footprint optimization and movement of manufacturing locations for certain products; disruptions to our manufacturing operations or those of our customers or suppliers; our ability to successfully identify, close, integrate and realize anticipated benefits from our acquisitions; quality issues or unanticipated costs in fulfilling our warranty obligations (including our discontinued solar inverter product line), and adequacy of our warranty reserves; risks inherent in our international operations, including the effect of export controls, the impact of tariffs on our supply chain or products we sell, political and geographical risks, and fluctuations in currency exchange rates; our ability to enforce, protect, and maintain our proprietary technology and intellectual property rights; regulatory risk related to our supply chain; legal matters, claims, investigations, and proceedings; changes to tax laws and regulations or our tax rates; changes in federal, state, local and foreign regulations, including with respect to trade compliance, privacy and data protection, supply chain, and environmental regulation; the effect of our debt obligations and restrictive covenants on our ability to operate our business; risks related to our unfunded pension obligations; our estimates of the fair value of intangible assets; the potential impact of dilution related to our convertible debt, hedge, and warrant transactions; and the risks and uncertainties described in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2025.

These risks and uncertainties could cause actual results to differ materially and adversely from those expressed in any forward-looking statements, and readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are made and based on information available to us on the date of this press release. Aspirational goals and targets discussed on the conference call or in the presentation materials should not be interpreted in any respect as guidance. We assume no obligation to update the information in this press release or provide the reasons why our actual results may differ.

ADVANCED ENERGY INDUSTRIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in millions, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

Year Ended

 

 

December 31,

September 30,

December 31,

 

 

2025

 

2024

 

2025

 

2025

 

2024

Revenue, net

 

$

489.4

 

$

415.4

 

$

463.3

 

$

1,798.8

 

$

1,482.0

 

Cost of revenue

 

 

300.3

 

 

260.8

 

 

288.9

 

 

1,121.4

 

 

952.7

 

Gross profit

 

 

189.1

 

 

154.6

 

 

174.4

 

 

677.4

 

 

529.3

 

Gross margin %

 

 

38.6

%

 

37.2

%

 

37.6

%

 

37.7

%

 

35.7

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

60.1

 

 

56.1

 

 

59.1

 

 

232.4

 

 

211.8

 

Selling, general, and administrative

 

 

63.4

 

 

58.2

 

 

59.8

 

 

242.4

 

 

224.6

 

Amortization of intangible assets

 

 

5.4

 

 

5.5

 

 

5.6

 

 

22.1

 

 

26.0

 

Restructuring, asset impairments, and other charges

 

 

3.6

 

 

1.0

 

 

0.7

 

 

12.5

 

 

30.3

 

Total operating expenses

 

 

132.5

 

 

120.8

 

 

125.2

 

 

509.4

 

 

492.7

 

Operating income

 

 

56.6

 

 

33.8

 

 

49.2

 

 

168.0

 

 

36.6

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

6.5

 

 

7.2

 

 

6.6

 

 

26.6

 

 

42.9

 

Interest expense

 

 

(4.1

)

 

(4.6

)

 

(4.2

)

 

(16.7

)

 

(25.1

)

Other income (expense), net

 

 

(1.8

)

 

4.1

 

 

0.7

 

 

(9.2

)

 

(2.0

)

Income from continuing operations, before income tax

 

 

57.2

 

 

40.5

 

 

52.3

 

 

168.7

 

 

52.4

 

Income tax provision (benefit)

 

 

4.7

 

 

(8.5

)

 

5.9

 

 

19.4

 

 

(3.9

)

Income from continuing operations

 

 

52.5

 

 

49.0

 

 

46.4

 

 

149.3

 

 

56.3

 

Loss from discontinued operations, net of income tax

 

 

(0.2

)

 

(0.1

)

 

(0.2

)

 

(0.9

)

 

(2.1

)

Net income

 

$

52.3

 

$

48.9

 

$

46.2

 

$

148.4

 

$

54.2

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted-average common shares outstanding

 

 

37.6

 

 

37.5

 

 

37.6

 

 

37.6

 

 

37.5

 

Diluted weighted-average common shares outstanding

 

 

40.2

 

 

38.0

 

 

38.5

 

 

38.6

 

 

37.8

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations:

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$

1.40

 

$

1.31

 

$

1.23

 

$

3.97

 

$

1.50

 

Diluted earnings per share

 

$

1.31

 

$

1.29

 

$

1.21

 

$

3.87

 

$

1.49

 

 

 

 

 

 

 

 

 

 

 

 

 

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

 

Basic loss per share

 

$

(0.01

)

$

 

$

(0.01

)

$

(0.02

)

$

(0.06

)

Diluted loss per share

 

$

 

$

 

$

(0.01

)

$

(0.02

)

$

(0.06

)

 

 

 

 

 

 

 

 

 

 

 

 

Net income:

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per share

 

$

1.39

 

$

1.30

 

$

1.23

 

$

3.95

 

$

1.45

 

Diluted earnings per share

 

$

1.30

 

$

1.29

 

$

1.20

 

$

3.84

 

$

1.43

 

 

ADVANCED ENERGY INDUSTRIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in millions)

 

 

 

 

 

 

 

 

 

December 31,

 

December 31,

 

 

2025

 

2024

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

791.2

 

$

722.1

Accounts receivables, net

 

 

325.2

 

 

265.3

Inventories

 

 

411.2

 

 

360.4

Other current assets

 

 

46.3

 

 

41.5

Total current assets

 

 

1,573.9

 

 

1,389.3

 

 

 

 

 

 

 

Property and equipment, net

 

 

272.8

 

 

185.6

Operating lease right-of-use assets

 

 

98.1

 

 

96.3

Other assets

 

 

182.5

 

 

155.3

Goodwill and intangible assets, net

 

 

418.5

 

 

435.4

Total assets

 

$

2,545.8

 

$

2,261.9

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

224.1

 

$

143.5

Other accrued expenses

 

 

183.8

 

 

153.0

Current debt

 

 

567.5

 

 

Current portion of operating lease liabilities

 

 

15.8

 

 

17.8

Total current liabilities

 

 

991.2

 

 

314.3

 

 

 

 

 

 

 

Long-term debt

 

 

 

 

564.7

Other long-term liabilities

 

 

184.0

 

 

176.3

Long-term liabilities

 

 

184.0

 

 

741.0

 

 

 

 

 

 

 

Total liabilities

 

 

1,175.2

 

 

1,055.3

Deferred compensation

 

 

7.8

 

 

3.5

 

 

 

 

 

 

 

Total stockholders’ equity

 

 

1,362.8

 

 

1,203.1

Total liabilities and stockholders’ equity

 

$

2,545.8

 

$

2,261.9

 

ADVANCED ENERGY INDUSTRIES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

(in millions)

 

 

 

 

 

 

 

 

 

Year Ended December 31,

 

 

2025

 

2024

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net income

 

$

148.4

 

 

$

54.2

 

Less: loss from discontinued operations, net of income tax

 

 

(0.9

)

 

 

(2.1

)

Income from continuing operations, net of income tax

 

 

149.3

 

 

 

56.3

 

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash from operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

62.0

 

 

 

68.5

 

Stock-based compensation

 

 

55.7

 

 

 

45.9

 

Amortization and write off of debt issuance costs and debt discount

 

 

3.2

 

 

 

3.8

 

Deferred income tax benefit

 

 

(13.8

)

 

 

(20.5

)

Other

 

 

0.8

 

 

 

1.2

 

Changes in operating assets and liabilities, net of assets acquired

 

 

(22.5

)

 

 

(22.2

)

Net cash from operating activities from continuing operations

 

 

234.7

 

 

 

133.0

 

Net cash from operating activities from discontinued operations

 

 

(1.4

)

 

 

(2.2

)

Net cash from operating activities

 

 

233.3

 

 

 

130.8

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Purchases of long-term investments

 

 

(2.4

)

 

 

(3.0

)

Purchases of property and equipment

 

 

(107.4

)

 

 

(56.8

)

Acquisitions, net of cash acquired

 

 

 

 

 

(13.8

)

Net cash from investing activities

 

 

(109.8

)

 

 

(73.6

)

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Payment of debt issuance costs

 

 

 

 

 

(0.1

)

Dividend payments

 

 

(15.6

)

 

 

(15.4

)

Payments on long-term borrowings

 

 

(1.9

)

 

 

(355.0

)

Payment of acquisition holdback

 

 

(1.5

)

 

 

 

Purchase and retirement of common stock

 

 

(30.2

)

 

 

(1.8

)

Net payments related to stock-based awards

 

 

(6.9

)

 

 

(4.8

)

Net cash from financing activities

 

 

(56.1

)

 

 

(377.1

)

 

 

 

 

 

 

 

EFFECT OF CURRENCY TRANSLATION ON CASH

 

 

1.7

 

 

 

(2.6

)

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

69.1

 

 

 

(322.5

)

CASH AND CASH EQUIVALENTS, beginning of period

 

 

722.1

 

 

 

1,044.6

 

CASH AND CASH EQUIVALENTS, end of period

 

$

791.2

 

 

$

722.1

 

 

ADVANCED ENERGY INDUSTRIES, INC.

SUPPLEMENTAL INFORMATION (UNAUDITED)

(in millions)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Revenue by Market

 

Three Months Ended

 

Year Ended

 

 

December 31,

 

September 30,

 

December 31,

 

 

2025

 

2024

 

2025

 

2025

 

2024

Semiconductor Equipment

 

$

211.6

 

$

226.8

 

$

196.6

 

$

839.9

 

$

792.5

Data Center Computing

 

 

177.9

 

 

88.7

 

 

171.6

 

 

587.3

 

 

284.2

Industrial and Medical

 

 

78.2

 

 

76.8

 

 

71.2

 

 

282.3

 

 

316.2

Telecom and Networking

 

 

21.7

 

 

23.1

 

 

23.9

 

 

89.3

 

 

89.1

Total

 

$

489.4

 

$

415.4

 

$

463.3

 

$

1,798.8

 

$

1,482.0

 

ADVANCED ENERGY INDUSTRIES, INC.

SELECTED OTHER DATA (UNAUDITED)

(in millions)

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of non-GAAP measures

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP gross profit, gross margin, operating expenses, operating income,

 

Three Months Ended

Year Ended

and operating margin

 

December 31,

September 30,

December 31,

 

 

2025

 

2024

 

2025

 

2025

 

2024

Gross profit from continuing operations, as reported

 

$

189.1

 

$

154.6

 

$

174.4

 

$

677.4

 

$

529.3

 

Adjustments to gross profit:

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

1.3

 

 

1.1

 

 

1.3

 

 

4.9

 

 

4.0

 

Facility, infrastructure, and other transition costs

 

 

3.9

 

 

2.1

 

 

5.5

 

 

14.7

 

 

4.5

 

Acquisition-related costs

 

 

 

 

0.1

 

 

 

 

 

 

 

Non-GAAP gross profit

 

 

194.3

 

 

157.9

 

 

181.2

 

 

697.0

 

 

537.8

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

 

38.6

%

 

37.2

%

 

37.6

%

 

37.7

%

 

35.7

%

Non-GAAP gross margin

 

 

39.7

%

 

38.0

%

 

39.1

%

 

38.7

%

 

36.3

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses from continuing operations, as reported

 

 

132.5

 

 

120.8

 

 

125.2

 

 

509.4

 

 

492.7

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

 

(5.4

)

 

(5.5

)

 

(5.6

)

 

(22.1

)

 

(26.0

)

Stock-based compensation

 

 

(13.2

)

 

(10.6

)

 

(13.3

)

 

(50.8

)

 

(41.9

)

Acquisition-related costs

 

 

(1.8

)

 

(1.2

)

 

(1.2

)

 

(5.8

)

 

(6.0

)

Facility, infrastructure, and other transition costs

 

 

(1.1

)

 

(0.7

)

 

(1.0

)

 

(5.2

)

 

(1.2

)

Restructuring, asset impairments, and other charges

 

 

(3.6

)

 

(1.0

)

 

(0.7

)

 

(12.5

)

 

(30.3

)

Non-GAAP operating expenses

 

 

107.4

 

 

101.8

 

 

103.4

 

 

413.0

 

 

387.3

 

Non-GAAP operating income

 

$

86.9

 

$

56.1

 

$

77.8

 

$

284.0

 

$

150.5

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP operating income

 

$

56.6

 

$

33.8

 

$

49.2

 

$

168.0

 

$

36.6

 

Adjustments to gross profit

 

 

5.2

 

 

3.3

 

 

6.8

 

 

19.6

 

 

8.5

 

Adjustments to operating expenses

 

 

25.1

 

 

19.0

 

 

21.8

 

 

96.4

 

 

105.4

 

Non-GAAP operating income

 

$

86.9

 

$

56.1

 

$

77.8

 

$

284.0

 

$

150.5

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP income from continuing operations

 

$

52.5

 

$

49.0

 

$

46.4

 

$

149.3

 

$

56.3

 

GAAP operating margin

 

 

11.6

%

 

8.1

%

 

10.6

%

 

9.3

%

 

2.5

%

Non-GAAP operating margin

 

 

17.8

%

 

13.5

%

 

16.8

%

 

15.8

%

 

10.2

%

 

ADVANCED ENERGY INDUSTRIES, INC.

SELECTED OTHER DATA (UNAUDITED)

(in millions, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of non-GAAP measure

 

Three Months Ended

 

Year Ended

Non-GAAP income, net of income tax

 

December 31,

 

September 30,

 

December 31,

 

 

2025

 

2024

 

2025

 

2025

 

2024

Income from continuing operations, net of income tax

 

$

52.5

 

 

$

49.0

 

 

$

46.4

 

 

$

149.3

 

 

$

56.3

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

 

5.4

 

 

 

5.5

 

 

 

5.6

 

 

 

22.1

 

 

 

26.0

 

Acquisition-related costs

 

 

1.8

 

 

 

1.3

 

 

 

1.2

 

 

 

5.8

 

 

 

6.0

 

Facility, infrastructure, and other transition costs

 

 

5.0

 

 

 

2.8

 

 

 

6.5

 

 

 

19.9

 

 

 

5.7

 

Restructuring, asset impairments, and other charges

 

 

3.6

 

 

 

1.0

 

 

 

0.7

 

 

 

12.5

 

 

 

30.3

 

Unrealized foreign currency loss (gain)

 

 

0.5

 

 

 

(4.2

)

 

 

(1.3

)

 

 

5.2

 

 

 

(3.4

)

Other costs included in other income (expense), net

 

 

 

 

 

(0.9

)

 

 

 

 

 

0.2

 

 

 

2.8

 

Stock-based compensation

 

 

14.5

 

 

 

11.9

 

 

 

14.6

 

 

 

55.7

 

 

 

45.9

 

Tax effect of non-GAAP adjustments, including certain discrete tax benefits

 

 

(8.2

)

 

 

(17.1

)

 

 

(7.3

)

 

 

(25.7

)

 

 

(29.2

)

Non-GAAP income, net of income tax

 

$

75.1

 

 

$

49.3

 

 

$

66.4

 

 

$

245.0

 

 

$

140.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of non-GAAP measure

 

Three Months Ended

 

Year Ended

Non-GAAP diluted weighted-average common shares

 

December 31,

 

September 30,

 

December 31,

 

 

2025

 

2024

 

2025

 

2025

 

2024

Diluted weighted-average common shares outstanding

 

 

40.2

 

 

 

38.0

 

 

 

38.5

 

 

 

38.6

 

 

 

37.8

 

Dilutive effect of convertible notes

 

 

(1.4

)

 

 

 

 

 

(0.4

)

 

 

(0.4

)

 

 

 

Non-GAAP diluted weighted-average common shares outstanding

 

 

38.8

 

 

 

38.0

 

 

 

38.1

 

 

 

38.2

 

 

 

37.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of non-GAAP measure

 

Three Months Ended

 

Year Ended

Non-GAAP earnings per share

 

December 31,

 

September 30,

 

December 31,

 

 

2025

 

2024

 

2025

 

2025

 

2024

Diluted earnings per share from continuing operations, as reported

 

$

1.31

 

$

1.29

 

$

1.21

 

$

3.87

 

$

1.49

Add back:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Per share impact of non-GAAP adjustments, net of tax

 

 

0.63

 

 

0.01

 

 

0.53

 

 

2.54

 

 

2.22

Non-GAAP earnings per share

 

$

1.94

 

$

1.30

 

$

1.74

 

$

6.41

 

$

3.71

 

ADVANCED ENERGY INDUSTRIES, INC.

SELECTED OTHER DATA (UNAUDITED)

(in millions, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Year Ended

Reconciliation of non-GAAP measure

 

December 31,

 

September 30,

 

December 31,

Non-GAAP provision for income taxes

 

2025

 

2024

 

2025

 

2025

 

2024

Provision (benefit) for income taxes, as reported

 

$

4.7

 

 

$

(8.5

)

 

$

5.9

 

 

$

19.4

 

 

$

(3.9

)

Adjustment:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP items and other discrete tax items excluding stock-based compensation

 

 

5.2

 

 

 

14.3

 

 

 

4.2

 

 

 

14.0

 

 

 

19.6

 

Tax effect of stock-based compensation

 

 

3.0

 

 

 

2.8

 

 

 

3.1

 

 

 

11.7

 

 

 

9.6

 

Non-GAAP provision for income taxes

 

$

12.9

 

 

$

8.6

 

 

$

13.2

 

 

$

45.1

 

 

$

25.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Year Ended

Reconciliation of non-GAAP measure

 

December 31,

 

September 30,

 

December 31,

Non-GAAP income before income taxes

 

2025

 

2024

 

2025

 

2025

 

2024

Income from continuing operations, before income tax

 

$

57.2

 

 

$

40.5

 

 

$

52.3

 

 

$

168.7

 

 

$

52.4

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

 

5.4

 

 

 

5.5

 

 

 

5.6

 

 

 

22.1

 

 

 

26.0

 

Stock-based compensation

 

 

14.5

 

 

 

11.9

 

 

 

14.6

 

 

 

55.7

 

 

 

45.9

 

Acquisition-related costs

 

 

1.8

 

 

 

1.3

 

 

 

1.2

 

 

 

5.8

 

 

 

6.0

 

Facility, infrastructure, and other transition costs

 

 

5.0

 

 

 

2.8

 

 

 

6.5

 

 

 

19.9

 

 

 

5.7

 

Restructuring, asset impairments, and other charges

 

 

3.6

 

 

 

1.0

 

 

 

0.7

 

 

 

12.5

 

 

 

30.3

 

Unrealized foreign currency loss (gain)

 

 

0.5

 

 

 

(4.2

)

 

 

(1.3

)

 

 

5.2

 

 

 

(3.4

)

Other costs included in other income (expense), net

 

 

 

 

 

(0.9

)

 

 

 

 

 

0.2

 

 

 

2.8

 

Non-GAAP income before income taxes

 

$

88.0

 

 

$

57.9

 

 

$

79.6

 

 

$

290.1

 

 

$

165.7

 

Effective tax rate, as reported

 

 

8.2

%

 

 

(21.0

)%

 

 

11.3

%

 

 

11.5

%

 

 

(7.4

)%

Non-GAAP effective tax rate

 

 

14.7

%

 

 

14.9

%

 

 

16.6

%

 

 

15.5

%

 

 

15.3

%

 

Reconciliation of Q1 2026 Guidance

Low End

High End

 

Revenue

 

$480 million

 

$520 million

 

Reconciliation of non-GAAP earnings per share

 

 

 

 

GAAP earnings per share

$

1.19

 

$

1.69

 

Stock-based compensation

 

0.35

 

 

0.35

 

Amortization of intangible assets

 

0.12

 

 

0.12

 

Restructuring expenses and other costs

 

0.15

 

 

0.15

 

Tax effects of excluded items

 

(0.12

)

 

(0.12

)

Non-GAAP earnings per share

$

1.69

 

$

2.19

 

 

For more information, contact:

Andrew Huang

Advanced Energy Industries, Inc.

970-407-6555

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Semiconductor Hardware Consumer Electronics Technology Telecommunications

MEDIA:

Logo
Logo

NMI Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

EMERYVILLE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) — NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $94.2 million, or $1.20 per diluted share, for the fourth quarter ended December 31, 2025, compared to $96.0 million, or $1.22 per diluted share, for the third quarter ended September 30, 2025 and $86.2 million, or $1.07 per diluted share, for the fourth quarter ended December 31, 2024. Net income for the full year ended December 31, 2025 was $388.9 million or $4.92 per diluted share, which compares to $360.1 million, or $4.43 per diluted share, for the year ended December 31, 2024.

Adam Pollitzer, President and Chief Executive Officer of National MI, said, “The fourth quarter capped another year of success for National MI. In 2025, we delivered strong operating performance, generated significant NIW volume and consistent growth in our insured portfolio, and achieved record financial results and a 16.2% return on equity. We have a strong customer franchise, a talented team driving us forward every day, an exceptionally high-quality book covered by a comprehensive set of risk transfer solutions, and a robust balance sheet supported by the significant earnings power of our platform. Looking forward, we’re well-positioned to continue delivering differentiated growth, returns and value for our shareholders.”

Selected fourth quarter 2025 highlights include:

  • Primary insurance-in-force at quarter end was $221.4 billion, compared to $218.4 billion at the end of the third quarter and $210.2 billion at the end of the fourth quarter of 2024.
  • Net premiums earned were $152.5 million, compared to $151.3 million in the third quarter and $143.5 million in the fourth quarter of 2024.
  • Total revenue was $180.7 million, compared to $178.7 million in the third quarter and $166.5 million in the fourth quarter of 2024.
  • Insurance claims and claim expenses were $21.2 million, compared to $18.6 million in the third quarter and $17.3 million in the fourth quarter of 2024. Loss ratio was 13.9%, compared to 12.3% in the third quarter and 12.0% in the fourth quarter of 2024.
  • Underwriting and operating expenses were $31.1 million, compared to $29.2 million in the third quarter and $31.1 million in the fourth quarter of 2024. Expense ratio was 20.4%, compared to 19.3% in the third quarter and 21.7% in the fourth quarter of 2024.
  • Net income was $94.2 million, compared to $96.0 million in the third quarter and $86.2 million in the fourth quarter of 2024. Diluted EPS was $1.20, compared to $1.22 in the third quarter and $1.07 in the fourth quarter of 2024.
  • Adjusted net income was $93.8 million, compared to $95.7 million in the third quarter and $86.1 million in the fourth quarter of 2024. Adjusted diluted EPS was $1.20, compared to $1.21 in the third quarter and $1.07 in the fourth quarter of 2024.
  • Shareholders’ equity was $2.6 billion at quarter end and book value per share was $33.98. Book value per share excluding the impact of net unrealized gains and losses in the investment portfolio was $34.58, up 4% compared to $33.32 in the third quarter and 16% compared to $29.80 in the fourth quarter of 2024.
  • Annualized return on equity for the quarter was 14.8%, compared to 15.6% in the third quarter and 15.6% in the fourth quarter of 2024. Annualized adjusted return on equity was 14.7%, compared to 15.5% in the third quarter and 15.6% in the fourth quarter of 2024.
  • At quarter-end, total PMIERs available assets were $3.5 billion and net risk-based required assets were $2.1 billion.
   
Quarter Ended

Quarter Ended

Quarter Ended

Change



(1)


Change



(1)

   
12/31/2025

9/30/2025

12/31/2024

Q/Q

Y/Y
INSURANCE METRICS ($billions)
Primary Insurance-in-Force $ 221.4   $ 218.4   $ 210.2   1 % 5 %
New Insurance Written – NIW   14.2     13.0     11.9   9 % 19 %
           
FINANCIAL HIGHLIGHTS (Unaudited, $millions, except per share amounts)
Net Premiums Earned $ 152.5   $ 151.3   $ 143.5   1 % 6 %
Net Investment Income   27.5     26.8     22.7   3 % 21 %
Insurance Claims and Claim Expenses   21.2     18.6     17.3   14 % 23 %
Underwriting and Operating Expenses   31.1     29.2     31.1   7 % %
Adjusted Net Income   93.8     95.7     86.1   (2 )%
9 %
Adjusted Diluted EPS $ 1.20   $ 1.21   $ 1.07   (1 )%
12 %
Book Value per Share (excluding net unrealized gains and losses) (2) $ 34.58   $ 33.32   $ 29.80   4 % 16 %
Loss Ratio   13.9 %   12.3 %   12.0 %    
Expense Ratio   20.4 %   19.3 %   21.7 %    

(1) Percentages may not be replicated based on the rounded figures presented in the table.
(2) Book value per share (excluding net unrealized gains and losses) is defined as total shareholders’ equity, excluding the after-tax effects of unrealized gains and losses on our investment portfolio, divided by shares outstanding.

Conference Call and Webcast Details

The company will hold a conference call, which will be webcast live today, February 10, 2026, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The webcast will be available on the company’s website, www.nationalmi.com, in the “Investor Relations” section. The conference call can also be accessed by dialing (844) 481-2708 in the U.S., or (412) 317-0664 internationally, by referencing NMI Holdings, Inc.

About NMI Holdings, Inc.

NMI Holdings, Inc. (NASDAQ: NMIH), is the parent company of National Mortgage Insurance Corporation (National MI), a U.S.-based, private mortgage insurance company enabling low down payment borrowers to realize home ownership while protecting lenders and investors against losses related to a borrower’s default. To learn more, please visit www.nationalmi.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release or any other written or oral statements made by or on behalf of the Company in connection therewith may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). The PSLRA provides a “safe harbor” for any forward-looking statements. All statements other than statements of historical fact included in or incorporated by reference in this release are forward-looking statements, including any statements about our expectations, outlook, beliefs, plans, predictions, forecasts, objectives, assumptions or future events or performance. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “believe,” “can,” “could,” “may,” “predict,” “assume,” “potential,” “should,” “will,” “estimate,” “perceive,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “intend” and similar words or phrases. All forward-looking statements are only predictions and involve estimates, known and unknown risks, assumptions and uncertainties that may turn out to be inaccurate and could cause actual results to differ materially from those expressed in them. Many risks and uncertainties are inherent in our industry and markets. Others are more specific to our business and operations. Important factors that could cause actual events or results to differ materially from those indicated in such statements include, but are not limited to: changes in general economic, market and political conditions and policies (including changes in interest rates and inflation) and investment results or other conditions that affect the U.S. housing market or the U.S. markets for home mortgages, mortgage insurance, reinsurance and credit risk transfer markets, including the risk related to geopolitical instability, inflation, an economic downturn (including any decline in home prices) or recession, international trade policies in areas such as tariffs or other trade restrictions, and their impacts on our business, operations and personnel; changes in the charters, business practices, policies, pricing or priorities of Fannie Mae and Freddie Mac (collectively, the GSEs), which may include decisions that have the impact of decreasing or discontinuing the use of mortgage insurance as credit enhancement generally, or with first time homebuyers or on very high loan-to-value mortgages; or changes in the direction of housing policy objectives of the Federal Housing Finance Agency (“FHFA”), such as the FHFA’s priority to increase the accessibility to and affordability of homeownership for low-and-moderate income borrowers and underrepresented communities; our ability to remain an eligible mortgage insurer under the private mortgage insurer eligibility requirements (“PMIERs”) and other requirements imposed by the GSEs, which they may change at any time; retention of our existing certificates of authority in each state and the District of Columbia (“D.C.”) and our ability to remain a mortgage insurer in good standing in each state and D.C.; our future profitability, liquidity and capital resources; actions of existing competitors, including other private mortgage insurers and government mortgage insurers such as the Federal Housing Administration, the U.S. Department of Agriculture’s Rural Housing Service and the U.S. Department of Veterans Affairs, and potential market entry by new competitors or consolidation of existing competitors; adoption of new or changes to existing laws, rules and regulations that impact our business or financial condition directly or the mortgage insurance industry generally or their enforcement and implementation by regulators, including the implementation of the final rules defining and/or concerning “Qualified Mortgage” and “Qualified Residential Mortgage”; U.S. federal tax reform and other potential changes in tax law and their impact on us and our operations; legislative or regulatory changes to the GSEs’ role in the secondary mortgage market or other changes that could affect the residential mortgage industry generally or mortgage insurance industry in particular; potential legal and regulatory claims, investigations, actions, audits or inquiries that could result in adverse judgments, settlements, fines or other reliefs that could require significant expenditures or have other negative effects on our business; our ability to successfully execute and implement our capital plans, including our ability to access the equity, credit and reinsurance markets and to enter into, and receive approval of, reinsurance arrangements on terms and conditions that are acceptable to us, the GSEs and our regulators; lenders, the GSEs, or other market participants seeking alternatives to private mortgage insurance; our ability to implement our business strategy, including our ability to write mortgage insurance on high quality low down payment residential mortgage loans, implement successfully and on a timely basis, complex infrastructure, systems, procedures, and internal controls to support our business and regulatory and reporting requirements of the insurance industry; our ability to attract and retain a diverse customer base, including the largest mortgage originators; failure of risk management or pricing or investment strategies; decrease in the length of time our insurance policies are in force; emergence of unexpected claim and coverage issues, including claims exceeding our reserves or amounts we had expected to experience; potential adverse impacts arising from natural disasters including, with respect to affected areas, a decline in new business, adverse effects on home prices, and an increase in notices of default on insured mortgages; climate risk and efforts to manage or regulate climate risk by government agencies could affect our business and operations; potential adverse impacts arising from the occurrence of any man-made disasters or public health emergencies, including pandemics; the inability of our counter-parties, including third party reinsurers, to meet their obligations to us; failure to maintain, improve and continue to develop necessary information technology systems or the failure of technology providers to perform; effectiveness and security of our information technology systems and digital products and services, including the risks these systems, products or services may fail to operate as expected or planned, or expose us to cybersecurity or third-party risks (including the exposure of our confidential customer and other information); and ability to recruit, train and retain key personnel. These risks and uncertainties also include, but are not limited to, those set forth under the heading “Risk Factors” detailed in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024, as subsequently updated through other reports we file with the SEC. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. We caution you not to place undue reliance on any forward-looking statement, which speaks only as of the date on which it is made, and we undertake no obligation to publicly update or revise any forward-looking statement to reflect new information, future events or circumstances that occur after the date on which the statement is made or to reflect the occurrence of unanticipated events except as required by law.

Use of Non-GAAP Financial Measures

We believe the use of the non-GAAP measures of adjusted income before tax, adjusted net income, adjusted diluted EPS, adjusted return-on-equity, adjusted expense ratio, adjusted combined ratio and book value per share (excluding net unrealized gains and losses) enhance the comparability of our fundamental financial performance between periods, and provide relevant information to investors. These non-GAAP financial measures align with the way the company’s business performance is evaluated by management. These measures are not prepared in accordance with GAAP and should not be viewed as alternatives to GAAP measures of performance. These measures have been presented to increase transparency and enhance the comparability of our fundamental operating trends across periods. Other companies may calculate these measures differently; their measures may not be comparable to those we calculate and present.

Adjusted income before tax is defined as GAAP income before tax, excluding the pre-tax effects of net realized gains or losses from our investment portfolio, periodic costs incurred in connection with capital markets transactions, and other infrequent, unusual or non-operating items in the periods in which such items are incurred.

Adjusted net income is defined as GAAP net income, excluding the after-tax effects of net realized gains or losses from our investment portfolio, periodic costs incurred in connection with capital markets transactions, and other infrequent, unusual or non-operating items in the periods in which such items are incurred. Adjustments to components of pre-tax income are tax effected using the applicable federal statutory tax rate for the respective periods.

Adjusted diluted EPS is defined as adjusted net income divided by adjusted weighted average diluted shares outstanding. Adjusted weighted average diluted shares outstanding is defined as weighted average diluted shares outstanding, adjusted for changes in the dilutive effect of non-vested shares that would otherwise have occurred had GAAP net income been calculated in accordance with adjusted net income. There will be no adjustment to weighted average diluted shares outstanding in the periods that non-vested shares are anti-dilutive under GAAP.

Adjusted return on equity is calculated by dividing adjusted net income on an annualized basis by the average shareholders’ equity for the period.

Adjusted expense ratio is defined as GAAP underwriting and operating expenses, excluding the pre-tax effects of periodic costs incurred in connection with capital markets transactions, divided by net premiums earned.

Adjusted combined ratio is defined as the total of GAAP underwriting and operating expenses, excluding the pre-tax effects of periodic costs incurred in connection with capital markets transactions and insurance claims and claims expenses, divided by net premiums earned.

Book value per share (excluding net unrealized gains and losses) is defined as total shareholders’ equity, excluding the after-tax effects of unrealized gains and losses on investments, divided by shares outstanding.

Although adjusted income before tax, adjusted net income, adjusted diluted EPS, adjusted return-on-equity, adjusted expense ratio, adjusted combined ratio and book value per share (excluding net unrealized gains and losses) exclude certain items that have occurred in the past and are expected to occur in the future, the excluded items: (1) are not viewed as part of the operating performance of our primary activities; or (2) are impacted by market, economic or regulatory factors and are not necessarily indicative of operating trends, or both. These adjustments, and the reasons for their treatment, are described below.

(1) Net realized investment gains and losses. The recognition of net realized investment gains or losses can vary significantly across periods as the timing is highly discretionary and is influenced by factors such as market opportunities, tax and capital profile, and overall market cycles that do not reflect our current period operating results.

(2) Capital markets transaction costs. Capital markets transaction costs result from activities that are undertaken to improve our debt profile or enhance our capital position through activities such as debt refinancing and capital markets reinsurance transactions that may vary in their size and timing due to factors such as market opportunities, tax and capital profile, and overall market cycles.

(3) Other infrequent, unusual or non-operating items. Items that are the result of unforeseen or uncommon events, and are not expected to recur with frequency in the future. Identification and exclusion of these items provide clarity about the impact special or rare occurrences may have on our current financial performance. Past adjustments under this category include infrequent, unusual or non-operating adjustments related to severance, restricted stock modification and other expenses incurred in connection with the CEO transition announced in September 2021 and the effects of the release of the valuation allowance recorded against our net federal and certain state net deferred tax assets in 2016 and the re-measurement of our net deferred tax assets in connection with tax reform in 2017. We believe such items are infrequent or non-recurring in nature, and are not indicative of the performance of, or ongoing trends in, our primary operating activities or business.

(4) Net unrealized gains and losses on investments. The recognition of net unrealized gains or losses on investment can vary significantly across periods and is influenced by factors such as interest rate movement, overall market and economic conditions, and tax and capital profiles. These valuation adjustments may not necessarily result in economic gains or losses and are not reflective of ongoing operations.

Investor Contact

John M. Swenson
Vice President, Investor Relations & Treasury
[email protected]



Consolidated statements of operations and comprehensive income (unaudited) For the three months ended
December 31,
  For the year ended
December 31,
    2025       2024       2025       2024  
  (In Thousands, except for per share data)
Revenues              
Net premiums earned $ 152,457     $ 143,520     $ 602,212     $ 564,688  
Net investment income   27,529       22,718       102,937       85,316  
Net realized investment gains   487       33       432       23  
Other revenues   263       233       859       944  
Total revenues   180,736       166,504       706,440       650,971  
Expenses              
Insurance claims and claim expenses   21,172       17,253       57,649       31,544  
Underwriting and operating expenses   31,069       31,092       119,908       118,397  
Service expenses   213       184       601       723  
Interest expense   7,133       7,102       28,478       36,896  
Total expenses   59,587       55,631       206,636       187,560  
               
Income before income taxes   121,149       110,873       499,804       463,411  
Income tax expense   26,932       24,706       110,878       103,305  
Net income $ 94,217     $ 86,167     $ 388,926     $ 360,106  
               
Earnings per share              
Basic $ 1.23     $ 1.09     $ 5.01     $ 4.51  
Diluted $ 1.20     $ 1.07     $ 4.92     $ 4.43  
               
Weighted average common shares outstanding              
Basic   76,700       78,997       77,626       79,844  
Diluted   78,208       80,623       79,038       81,273  
               
Loss ratio (1)   13.9 %     12.0 %     9.6 %     5.6 %
Expense ratio (2)   20.4 %     21.7 %     19.9 %     21.0 %
Combined ratio   34.3 %     33.7 %     29.5 %     26.6 %

(1) Loss ratio is calculated by dividing insurance claims and claim expenses by net premiums earned.
(2) Expense ratio is calculated by dividing underwriting and operating expenses by net premiums earned.

Consolidated balance sheets (unaudited) December 31, 2025   December 31, 2024
Assets (In Thousands, except for share data)
Fixed maturities, available-for-sale, at fair value (amortized cost of $3,190,174 and $2,876,343) $ 3,137,023     $ 2,723,541  
Cash and cash equivalents   43,937       54,308  
Premiums receivable, net   86,259       82,804  
Accrued investment income   27,253       22,386  
Deferred policy acquisition costs, net   64,372       64,327  
Software and equipment, net   21,727       25,681  
Intangible assets and goodwill   3,634       3,634  
Reinsurance recoverable   38,577       32,260  
Prepaid federal income taxes   400,258       322,175  
Other assets   18,058       18,857  
Total assets $ 3,841,098     $ 3,349,973  
       
Liabilities      
Debt $ 417,031     $ 415,146  
Unearned premiums   46,660       65,217  
Accounts payable and accrued expenses   101,595       103,164  
Reserve for insurance claims and claim expenses   196,429       152,071  
Deferred tax liability, net   478,890       386,192  
Other liabilities   8,507       10,751  
Total liabilities   1,249,112       1,132,541  
       
Shareholders’ equity      
Common stock – 76,285,242 and 78,600,726 shares outstanding as of December 31, 2025 and December 31, 2024, respectively   884       879  
Additional paid-in capital   1,016,772       1,004,692  
Treasury stock, at cost: 12,086,223 and 9,301,900 common shares as of December 31, 2025 and December 31, 2024, respectively   (351,772 )     (246,594 )
Accumulated other comprehensive loss, net of tax   (46,083 )     (124,804 )
Retained earnings   1,972,185       1,583,259  
Total shareholders’ equity   2,591,986       2,217,432  
Total liabilities and shareholders’ equity $ 3,841,098     $ 3,349,973  

Non-GAAP Financial Measure Reconciliations (unaudited)
  As of and for the three months ended   For the year ended December 31,
  12/31/2025   9/30/2025   12/31/2024     2025       2024  
As Reported (In Thousands, except for per share data)
Revenues                  
Net premiums earned $ 152,457     $ 151,323     $ 143,520     $ 602,212     $ 564,688  
Net investment income   27,529       26,773       22,718       102,937       85,316  
Net realized investment gains   487       321       33       432       23  
Other revenues   263       262       233       859       944  
Total revenues   180,736       178,679       166,504       706,440       650,971  
Expenses                  
Insurance claims and claim expenses   21,172       18,554       17,253       57,649       31,544  
Underwriting and operating expenses   31,069       29,156       31,092       119,908       118,397  
Service expenses   213       162       184       601       723  
Interest expense   7,133       7,124       7,102       28,478       36,896  
Total expenses   59,587       54,996       55,631       206,636       187,560  
                   
Income before income taxes   121,149       123,683       110,873       499,804       463,411  
Income tax expense   26,932       27,684       24,706       110,878       103,305  
Net income $ 94,217     $ 95,999     $ 86,167     $ 388,926     $ 360,106  
                   
Adjustments:                  
Net realized investment gains   (487 )     (321 )     (33 )     (432 )     (23 )
Capital markets transaction costs                           6,966  
Adjusted income before taxes   120,662       123,362       110,840       499,372       470,354  
                   
Income tax (benefit) expense on adjustments (1)   (102 )     (67 )     (7 )     (90 )     1,458  
Adjusted net income $ 93,832     $ 95,745     $ 86,141     $ 388,584     $ 365,591  
                   
Weighted average diluted shares outstanding   78,208       78,830       80,623       79,038       81,273  
                   
Diluted EPS $ 1.20     $ 1.22     $ 1.07     $ 4.92     $ 4.43  
Adjusted diluted EPS $ 1.20     $ 1.21     $ 1.07     $ 4.92     $ 4.50  
                   
Return on equity   14.8 %     15.6 %     15.6 %     16.2 %     17.4 %
Adjusted return on equity   14.7 %     15.5 %     15.6 %     16.2 %     17.6 %
                   
Expense ratio

(2)
  20.4 %     19.3 %     21.7 %     19.9 %     21.0 %
Adjusted expense ratio

(3)
  20.4 %     19.3 %     21.7 %     19.9 %     21.0 %
                   
Combined ratio

(4)
  34.3 %     31.5 %     33.7 %     29.5 %     26.6 %
Adjusted combined ratio

(5)
  34.3 %     31.5 %     33.7 %     29.5 %     26.6 %
                   
Book value per share

(6)
$ 33.98     $ 32.62     $ 28.21          
Book value per share (excluding net unrealized gains and losses)

(7)
$ 34.58     $ 33.32     $ 29.80          

(1) Marginal tax impact of non-GAAP adjustments is calculated based on our statutory U.S. federal corporate income tax rate of 21%, except for those items that are not eligible for an income tax deduction.
(2) Expense ratio is calculated by dividing underwriting and operating expenses by net premiums earned.
(3) Adjusted expense ratio is calculated by dividing adjusted underwriting and operating expense (underwriting and operating expenses excluding costs related to capital markets reinsurance transactions) by net premiums earned.
(4) Combined ratio is calculated by dividing the total of underwriting and operating expenses and insurance claims and claim expenses by net premiums earned.
(5) Adjusted combined ratio is calculated by dividing the total of adjusted underwriting and operating expenses (underwriting and operating expenses excluding costs related to capital market reinsurance transaction) and insurance claims and claim expenses by net premiums earned.
(6) Book value per share is calculated by dividing total shareholders’ equity by shares outstanding.
(7) Book value per share (excluding net unrealized gains and losses) is defined as total shareholders’ equity, excluding the after-tax effects of unrealized gains and losses on our investment portfolio, divided by shares outstanding.

Historical Quarterly Data   2025       2024  
  December 31   September 30   June 30   March 31   December 31
  (In Thousands, except for per share data)
Revenues                  
Net premiums earned $ 152,457     $ 151,323     $ 149,066     $ 149,366     $ 143,520  
Net investment income   27,529       26,773       24,949       23,686       22,718  
Net realized investment gains (losses)   487       321       (400 )     24       33  
Other revenues   263       262       164       170       233  
Total revenues   180,736       178,679       173,779       173,246       166,504  
Expenses                  
Insurance claims and claim expenses   21,172       18,554       13,445       4,478       17,253  
Underwriting and operating expenses   31,069       29,156       29,508       30,175       31,092  
Service expenses   213       162       110       116       184  
Interest expense   7,133       7,124       7,115       7,106       7,102  
Total expenses   59,587       54,996       50,178       41,875       55,631  
                   
Income before income taxes   121,149       123,683       123,601       131,371       110,873  
Income tax expense   26,932       27,684       27,450       28,812       24,706  
Net income $ 94,217     $ 95,999     $ 96,151     $ 102,559     $ 86,167  
                   
Earnings per share                  
Basic $ 1.23     $ 1.24     $ 1.23     $ 1.31     $ 1.09  
Diluted $ 1.20     $ 1.22     $ 1.21     $ 1.28     $ 1.07  
                   
Weighted average common shares outstanding                  
Basic   76,700       77,410       77,987       78,407       78,997  
Diluted   78,208       78,830       79,256       79,858       80,623  
                   
Other data                  
Loss ratio (1)   13.9 %     12.3 %     9.0 %     3.0 %     12.0 %
Expense ratio (2)   20.4 %     19.3 %     19.8 %     20.2 %     21.7 %
Combined ratio (3)   34.3 %     31.5 %     28.8 %     23.2 %     33.7 %

(1) Loss ratio is calculated by dividing insurance claims and claim expenses by net premiums earned.
(2) Expense ratio is calculated by dividing underwriting and operating expenses by net premiums earned.
(3) Combined ratio may not foot due to rounding.


Portfolio Statistics

The table below highlights trends in our primary portfolio as of the date and for the periods indicated.

Primary portfolio trends As of and for the three months ended
  December 31,
2025
  September 30,
2025
  June 30,
2025
  March 31,
2025
  December 31,
2024
  ($ Values In Millions, except as noted below)
New insurance written (NIW) $ 14,203     $ 13,012     $ 12,464     $ 9,221     $ 11,925  
New risk written   3,631       3,399       3,260       2,428       3,134  
Insurance-in-force (IIF) (1)   221,448       218,376       214,653       211,308       210,183  
Risk-in-force (RIF) (1)   59,313       58,538       57,496       56,515       56,113  
Policies in force (count) (1)   684,058       677,010       668,638       661,490       659,567  
Average loan size ($ value in thousands) (1) $ 324     $ 323     $ 321     $ 319     $ 319  
Coverage percentage (2)   26.8 %     26.8 %     26.8 %     26.7 %     26.7 %
Loans in default (count) (1)   7,661       7,093       6,709       6,859       6,642  
Default rate (1)   1.12 %     1.05 %     1.00 %     1.04 %     1.01 %
Risk-in-force on defaulted loans (1) $ 656     $ 600     $ 569     $ 567     $ 545  
Average net premium yield (3)   0.28 %     0.28 %     0.28 %     0.28 %     0.27 %
Earnings from cancellations $ 0.8     $ 0.7     $ 0.7     $ 0.6     $ 0.8  
Annual persistency (4)   83.4 %     83.9 %     84.1 %     84.3 %     84.6 %
Quarterly run-off (5)   5.1 %     4.3 %     4.3 %     3.9 %     4.5 %

(1) Reported as of the end of the period.
(2) Calculated as end of period RIF divided by end of period IIF.
(3) Calculated as net premiums earned, divided by average primary IIF for the period, annualized.
(4) Defined as the percentage of IIF that remains on our books after a given twelve-month period.
(5) Defined as the percentage of IIF that is no longer on our books after a given three-month period.


NIW, IIF and Premiums

The tables below present NIW and primary IIF, as of the dates and for the periods indicated.

NIW For the three months ended
  December 31, 2025   September 30, 2025   June 30, 2025   March 31, 2025   December 31, 2024
  (In Millions)
Monthly $ 13,841   $ 12,727   $ 12,214   $ 9,049   $ 11,688
Single   362     285     250     172     237
Total $ 14,203   $ 13,012   $ 12,464   $ 9,221   $ 11,925

Primary IIF As of
  December 31,
2025
  September 30,
2025
  June 30, 2025   March 31, 2025   December 31,
2024
  (In Millions)
Monthly $ 204,925   $ 201,671   $ 197,608   $ 193,856   $ 192,228
Single   16,523     16,705     17,045     17,452     17,955
Total $ 221,448   $ 218,376   $ 214,653   $ 211,308   $ 210,183


The following table presents the amounts related to the company’s quota-share reinsurance transactions (the 2018 QSR Transaction, 2020 QSR Transaction, 2021 QSR Transaction, 2022 QSR Transaction, 2022 Seasoned QSR Transaction, 2023 QSR Transaction, 2024 QSR Transaction, and 2025 QSR Transaction and collectively, the QSR Transactions), traditional reinsurance transactions (the 2022-1 XOL Transaction, 2022-2 XOL Transaction, 2022-3 XOL Transaction, 2023-1 XOL Transaction, 2023-2 XOL Transaction, 2024 XOL Transaction, and 2025 XOL Transaction and collectively, the XOL Transactions), and insurance-linked note transactions (the 2021-1 ILN Transaction, and 2021-2 ILN Transaction and collectively, the ILN Transactions) for the periods indicated.

  For the three months ended
  December 31,
2025
  September 30,
2025
  June 30, 2025   March 31,
2025
  December 31,
2024
  (In Thousands)
The QSR Transactions (1)                  
Ceded risk-in-force $ 12,805,761     $ 12,699,082     $ 12,764,708     $ 12,888,870     $ 13,024,200  
Ceded premiums earned   (40,131 )     (39,847 )     (40,227 )     (41,011 )     (41,596 )
Ceded claims and claim expenses   4,682       4,123       3,253       523       4,075  
Ceding commission earned   10,182       10,246       9,669       9,768       9,997  
Profit commission   18,310       19,083       19,958       23,398       20,149  
The XOL Transactions                  
Ceded premiums $ (11,037 )   $ (10,656 )   $ (10,350 )   $ (10,168 )   $ (9,969 )
The ILN Transactions (2)                  
Ceded premiums $ (3,007 )   $ (3,036 )   $ (3,244 )   $ (3,311 )   $ (4,217 )

(1) Effective July 1, 2025, NMIC terminated its coverage with all reinsurers under the 2016 QSR Transaction by mutual agreement on a cut-off basis.
(2) Effective December 27, 2024, NMIC exercised its optional termination rights to terminate and commute its previously outstanding excess-of-loss reinsurance agreements with Oaktown Re V Ltd., respectively. In connection with the terminations and commutations, the insurance-linked notes issued by Oaktown Re V Ltd. were redeemed in full with a distribution of remaining collateral assets.

The tables below present our total NIW by FICO, loan-to-value (LTV) ratio, and purchase/refinance mix for the periods indicated.

NIW by FICO For the three months ended   For the year ended
  December 31,
2025
  September 30,
2025
  December 31,
2024
  December 31,
2025
  December 31,
2024
  (In Millions)
>= 760 $ 7,907   $ 6,789   $ 6,508   $ 26,190   $ 24,808
740-759   2,620     2,395     2,090     9,049     8,098
720-739   1,654     1,626     1,621     6,042     5,907
700-719   1,010     1,094     890     3,830     3,794
680-699   569     617     575     2,189     2,392
<=679   443     491     241     1,600     1,045
Total $ 14,203   $ 13,012   $ 11,925   $ 48,900   $ 46,044
Weighted average FICO   759     756     758     757     757

NIW by LTV For the three months ended   For the year ended
  December 31,
2025
  September 30,
2025
  December 31,
2024
  December 31,
2025
  December 31,
2024
  (In Millions)
95.01% and above $ 1,606     $ 1,566     $ 1,510     $ 5,863     $ 5,908  
90.01% to 95.00%   5,970       5,809       5,370       21,539       21,149  
85.01% to 90.00%   4,627       4,062       3,740       15,327       13,994  
85.00% and below   2,000       1,575       1,305       6,171       4,993  
Total $ 14,203     $ 13,012     $ 11,925     $ 48,900     $ 46,044  
Weighted average LTV   91.6 %     92.1 %     92.1 %     91.9 %     92.3 %

NIW by purchase/refinance mix For the three months ended   For the year ended
  December 31,
2025
  September 30,
2025
  December 31,
2024
  December 31,
2025
  December 31,
2024
  (In Millions)
Purchase $ 11,840   $ 12,416   $ 10,799   $ 44,891   $ 43,921
Refinance   2,363     596     1,126     4,009     2,123
Total $ 14,203   $ 13,012   $ 11,925   $ 48,900   $ 46,044


The table below presents a summary of our primary IIF and RIF by book year as of December 31, 2025.

Primary IIF and RIF As of December 31, 2025
  IIF   RIF
Book Year (In Millions)
2025 $ 46,034   $ 11,977
2024   37,483     9,968
2023   28,761     7,611
2022   41,551     11,188
2021   40,887     11,331
2020 and before   26,732     7,238
Total $ 221,448   $ 59,313


The tables below present our total primary IIF and RIF by FICO and LTV, and total primary RIF by loan type as of the dates indicated.

Primary IIF by FICO As of
  December 31, 2025   September 30, 2025   December 31, 2024
  (In Millions)
>= 760 $ 111,255   $ 109,470   $ 105,315
740-759   40,008     39,273     37,321
720-739   30,503     30,275     29,343
700-719   20,491     20,355     19,766
680-699   13,448     13,447     13,374
<=679   5,743     5,556     5,064
Total $ 221,448   $ 218,376   $ 210,183

Primary RIF by FICO As of
  December 31, 2025   September 30, 2025   December 31, 2024
  (In Millions)
>= 760 $ 29,500   $ 29,084   $ 27,883
740-759   10,787     10,589     10,006
720-739   8,275     8,211     7,926
700-719   5,619     5,575     5,383
680-699   3,672     3,662     3,615
<=679   1,460     1,417     1,300
Total $ 59,313   $ 58,538   $ 56,113

Primary IIF by LTV As of
  December 31, 2025   September 30, 2025   December 31, 2024
  (In Millions)
95.01% and above $ 26,739   $ 25,978   $ 23,555
90.01% to 95.00%   109,228     107,914     103,472
85.01% to 90.00%   66,285     65,815     64,290
85.00% and below   19,196     18,669     18,866
Total $ 221,448   $ 218,376   $ 210,183

Primary RIF by LTV As of
  December 31, 2025   September 30, 2025   December 31, 2024
  (In Millions)
95.01% and above $ 8,404   $ 8,151   $ 7,345
90.01% to 95.00%   32,223     31,850     30,563
85.01% to 90.00%   16,412     16,318     15,956
85.00% and below   2,274     2,219     2,249
Total $ 59,313   $ 58,538   $ 56,113

Primary RIF by Loan Type As of
  December 31, 2025   September 30, 2025   December 31, 2024
           
Fixed 98 %   98 %   98 %
Adjustable rate mortgages:          
Less than five years          
Five years and longer 2     2     2  
Total 100 %   100 %   100 %


The table below presents a summary of the change in total primary IIF during the periods indicated.

Primary IIF As of and for the three months ended
  December 31, 2025   September 30, 2025   December 31, 2024
  (In Millions)
IIF, beginning of period $ 218,376     $ 214,653     $ 207,538  
NIW   14,203       13,012       11,925  
Cancellations, principal repayments and other reductions   (11,131 )     (9,289 )     (9,280 )
IIF, end of period $ 221,448     $ 218,376     $ 210,183  



Geographic Dispersion

The following table shows the distribution by state of our primary RIF as of the periods indicated:

Top 10 primary RIF by state As of
  December 31, 2025   September 30, 2025   December 31, 2024
California 10.1 %   10.1 %   10.1 %
Texas 8.3     8.3     8.6  
Florida 7.2     7.2     7.3  
Georgia 4.0     4.0     4.1  
Illinois 4.0     4.0     3.8  
Virginia 3.7     3.7     3.7  
Washington 3.6     3.7     3.9  
Pennsylvania 3.5     3.5     3.4  
Ohio 3.5     3.4     3.3  
New York 3.3     3.3     3.2  
Total 51.2 %   51.2 %   51.4 %


The table below presents selected primary portfolio statistics, by book year, as of December 31, 2025.

  As of December 31, 2025
Book Year Original
Insurance
Written
  Remaining
Insurance
in Force
  %
Remaining
of Original
Insurance
  Policies
Ever in
Force
  Number of
Policies in
Force
  Number
of Loans
in Default
  # of
Claims
Paid
  Incurred
Loss Ratio
(Inception
to Date)


(1)
  Cumulative
Default
Rate


(2)
  Current
Default
Rate


(3)
  ($ Values in Millions)    
2016 and prior $ 37,222   $ 1,795   5 %   151,615   9,581   186   417   2.1 %   0.4 %   1.9 %
2017   21,582     1,489   7 %   85,897   8,609   222   193   2.0 %   0.5 %   2.6 %
2018   27,295     1,939   7 %   104,043   10,683   349   210   2.4 %   0.5 %   3.3 %
2019   45,141     5,067   11 %   148,423   23,037   447   123   2.0 %   0.4 %   1.9 %
2020   62,702     16,442   26 %   186,174   59,727   537   71   1.3 %   0.3 %   0.9 %
2021   85,574     40,887   48 %   257,972   140,027   1,650   161   3.3 %   0.7 %   1.2 %
2022   58,734     41,551   71 %   163,281   123,834   2,204   249   16.6 %   1.5 %   1.8 %
2023   40,473     28,761   71 %   111,994   85,236   1,097   72   15.7 %   1.0 %   1.3 %
2024   46,044     37,483   81 %   120,747   103,277   818   12   14.5 %   0.7 %   0.8 %
2025   48,900     46,034   94 %   125,570   120,047   151     6.4 %   0.1 %   0.1 %
Total $ 473,667   $ 221,448       1,455,716   684,058   7,661   1,508            

(1) Calculated as total claims incurred (paid and reserved) divided by cumulative premiums earned, net of reinsurance.
(2) Calculated as the sum of the number of claims paid ever to date and number of loans in default divided by policies ever in force.
(3) Calculated as the number of loans in default divided by number of policies in force.

The following table provides a reconciliation of the beginning and ending reserve balances for primary insurance claims and claim expenses:

  For the three months ended December 31,   For the year ended December 31,
    2025       2024       2025       2024  
  (In Thousands)
Beginning balance $ 180,347     $ 135,520     $ 152,071     $ 123,974  
Less reinsurance recoverables (1)   (35,315 )     (29,214 )     (32,260 )     (27,514 )
Beginning balance, net of reinsurance recoverables   145,032       106,306       119,811       96,460  
               
Add claims incurred:              
Claims and claim expenses incurred:              
Current year (2)   26,137       21,674       114,721       93,206  
Prior years (3)   (5,449 )     (4,421 )     (57,889 )     (61,662 )
Total claims and claim expenses incurred (4)   20,688       17,253       56,832       31,544  
               
Less claims paid:              
Claims and claim expenses paid:              
Current year (2)   1,325       458       1,605       638  
Prior years (3)   6,543       3,290       19,150       7,555  
Reinsurance terminations (5)               (1,964 )      
Total claims and claim expenses paid   7,868       3,748       18,791       8,193  
               
Reserve at end of period, net of reinsurance recoverables   157,852       119,811       157,852       119,811  
Add reinsurance recoverables (1)   38,577       32,260       38,577       32,260  
Ending balance $ 196,429     $ 152,071     $ 196,429     $ 152,071  

(1) Related to ceded losses recoverable under the QSR Transactions.
(2) Related to insured loans with their most recent defaults occurring in the current year. For example, if a loan defaulted in a prior year and subsequently cured and later re-defaulted in the current year, the default would be included in the current year. Amounts are presented net of reinsurance and included $102.0 million attributed to net case reserves and $10.8 million attributed to net IBNR reserves for the year ended December 31, 2025, $83.5 million attributed to net case reserves and $8.1 million attributed to net IBNR reserves for the year ended December 31, 2024.
(3) Related to insured loans with defaults occurring in prior years, which have been continuously in default before the start of the current year. Amounts are presented net of reinsurance and included $48.4 million attributed to net case reserves and $8.1 million attributed to net IBNR reserves for the year ended December 31, 2025, $54.1 million attributed to net case reserves and $6.3 million attributed to net IBNR reserves for the year ended December 31, 2024.
(4) Excludes aggregate fees $0.8 million for the year ended December 31, 2025 incurred in connection with the termination or amendment of certain QSR Transactions.
(5) Represents the settlement of reinsurance recoverables in conjunction with the termination or amendment of certain QSR Transactions.

The following table provides a reconciliation of the beginning and ending count of loans in default:

  For the three months ended December 31,   For the year ended December 31,
  2025
  2024
  2025
  2024
Beginning default inventory 7,093     5,712     6,642     5,099  
Plus: new defaults 2,821     2,742     9,940     8,757  
Less: cures (2,074 )   (1,684 )   (8,427 )   (6,899 )
Less: claims paid (164 )   (108 )   (445 )   (276 )
Less: rescission and claims denied (15 )   (20 )   (49 )   (39 )
Ending default inventory 7,661     6,642     7,661     6,642  


The following table provides details of our claims paid, before giving effect to claims ceded under the QSR Transactions, for the periods indicated:

  For the three months ended December 31,   For the year ended December 31,
    2025       2024       2025       2024  
  ($ Values In Thousands)
Number of claims paid (1)   164       108       445       276  
Total amount paid for claims $ 9,772     $ 4,777     $ 25,873     $ 10,491  
Average amount paid per claim $ 60     $ 44     $ 58     $ 38  
Severity (2)   81 %     65 %     76 %     61 %

(1) Count includes 21 and 71 claims settled without payment during the three months and year ended December 31, 2025, respectively, and 32 and 88 claims settled without payment during the three months and year ended December 31, 2024, respectively.
(2) Severity represents the total amount of claims paid including claim expenses divided by the related RIF on the loan at the time the claim is perfected, and is calculated including claims settled without payment.

The following table shows our average reserve per default, before giving effect to reserves ceded under the QSR Transactions, as of the dates indicated:

Average reserve per default: As of
  December 31, 2025   December 31, 2024
  (In Thousands)
Case (1) $ 23.5   $ 21.0
IBNR (1) (2)   2.1     1.9
Total $ 25.6   $ 22.9

(1) Defined as the gross reserve per insured loan in default.
(2) Amount includes claims adjustment expenses.

The following table provides a comparison of the PMIERs available assets and net risk-based required asset amount as reported by NMIC as of the dates indicated:

  As of
  December 31, 2025   September 30, 2025   December 31, 2024
  (In Thousands)
Available assets $ 3,496,971   $ 3,369,950   $ 3,108,211
Net risk-based required assets   2,058,467     2,003,410     1,828,807



Belpointe OZ Announces Aster & Links Reaches Leasing Milestone

Sarasota, Florida, Feb. 10, 2026 (GLOBE NEWSWIRE) — Belpointe PREP, LLC (“Belpointe OZ,” “we,” “us,” “our” or the “Company”) (NYSE American: OZ), a publicly traded qualified opportunity fund, today announced that its flagship asset, Aster & Links, a premier 424-unit mixed-use luxury apartment community in downtown Sarasota, Florida, has successfully leased approximately two-thirds of its residential units.

This leasing milestone reflects continued progress in the project’s lease-up phase and, in our view, underscores the sustained demand for high-quality rental housing in downtown Sarasota. As occupancy increases, Aster & Links continues advancing toward stabilization while building a growing residential community.

Situated in the heart of downtown Sarasota, Aster & Links offers residents an elevated living experience with thoughtfully designed and spacious one-, two- and three-bedroom apartments, many featuring powder rooms or dens well-suited for entertaining. Two-level penthouses include soaring ceilings, townhome-style layouts, and premium appliance packages. The community is complemented by a robust amenity offering and a highly walkable location near many of Sarasota’s arts, dining, and waterfront destinations.

“We are encouraged by the continued leasing momentum at Aster & Links,” said Brandon Lacoff, Chief Executive Officer of Belpointe OZ. “Reaching approximately two-thirds leased represents meaningful progress as the property continues its transition toward stabilization and, we believe, reflects the continued strength of the Sarasota residential market.”

In addition to its residential component, Aster & Links boasts approximately 60,000 square feet of curated retail, featuring existing retailers: Sprouts Farmers Market®, OfKors® Cafe, Isabel Boutique, ServisFirst Bank, SkinSpirit®, upcoming retailers: Pause® Studio, Embers Pilates, and Atelier + Design, and additional retailers anticipated.

For additional information or to schedule a private tour, please visit asterandlinks.com or call 888-680-3897.

About Aster & Links

Aster & Links is a premier mixed-use luxury community located in downtown Sarasota, Florida. The development combines sophisticated rental residences with neighborhood-serving retail in a walkable urban setting. Designed with modern living in mind, Aster & Links offers upscale amenities, distinctive architecture, and access to Sarasota’s cultural, dining, and waterfront attractions. Learn more at asterandlinks.com or by calling 888-680-3897.

About Belpointe OZ

Belpointe OZ is a publicly traded qualified opportunity fund, listed on NYSE American under the symbol “OZ.” To date, Belpointe OZ has over 2,000 units in its development pipeline throughout four cities, representing an approximate total project cost of over $1.0 billion.

Belpointe OZ has filed a registration statements (including a combined prospectus) with the U.S. Securities and Exchange Commission (“SEC”) for the offer and sale of up to an aggregate of $750,000,000 of Class A units representing limited liability interests in Belpointe OZ (the “Class A units”). Before you invest, you should read Belpointe OZ’s most recent prospectus and the other documents that it has filed with the SEC for more complete information about Belpointe OZ and the offering. Investing in Belpointe OZ’s Class A units involves a high degree of risk, including a complete loss of investment. Prior to making an investment decision, you should carefully consider Belpointe OZ’s investment objectives and strategy, risk factors, fees and expenses and any tax consequences that may results from an investment in Belpointe OZ’s Class A units. To view Belpointe OZ’s most recent prospectus containing this and other important information visit sec.gov or investors.belpointeoz.com. Alternatively, you may request Belpointe OZ send you the prospectus by calling (203) 883-1944 or emailing [email protected]. Read the prospectus in its entirety before making an investment decision.

Cautionary Note Regarding Forward-Looking Statements

This press release (this “Press Release”) contains express or implied “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to qualify for the “safe harbor” from liability established by those sections. Forward-looking statements are based on our current beliefs and assumptions, and on information currently available to us, and only speak as of the date of this Press Release. All statements other than statements of historical fact, such as statements containing estimates, projections and other forward-looking information, are forward-looking statements. Forward-looking statements are typically identified by words and phrases such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “will,” “would,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” or the negative of such words and other comparable terminology. However, the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and involve risks, uncertainties and other factors beyond our control, including factors described in our filings with the SEC, such as those detailed under the heading “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q. We cannot provide you with assurance that any of the assumptions upon which our forward-looking statements are based will prove to be correct. Should one or more risks materialize, or should our underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements, and you are therefore cautioned against placing undue reliance on any forward-looking statements. Except as otherwise required by applicable law, including federal securities laws, we do not intend to update or revise any forward-looking statements as a result of new information, future events, actual results, revised expectations or otherwise We further expressly disclaim any written or oral statements made by a third party regarding the subject matter of this Press Release.

Investor Relations and Media Contact:

Cody H. Laidlaw
Belpointe PREP, LLC
255 Glenville Road
Greenwich, Connecticut 06831
[email protected]
203-883-1944



Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

Product Sales Excluding Veklury Increased 4%Year-Over-Year to $28.0 billionfor Full Year 2025

Biktarvy Sales Increased7% Year-Over-Year to $14.3 billion for Full Year 2025

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

“Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “In 2026, our potential new launches include two cancer therapies and an additional HIV treatment option, and we look forward to building on the launches of Yeztugo and Livdelzi for liver disease. As we continue to increase our positive impact on healthcare, Gilead is well positioned for continued growth in 2026 and beyond.”

Fourth Quarter 2025 Financial Results

  • Total fourth quarter 2025 revenues increased 5% to $7.9 billion compared to the same period in 2024, primarily driven by higher sales of HIV and Liver Disease products, partially offset by lower sales of Veklury® (remdesivir).

  • Diluted earnings per share (“EPS”) was $1.74 in the fourth quarter 2025 compared to $1.42 in the same period in 2024. The increase was primarily driven by higher income tax benefits, net unrealized gains from equity securities and higher product sales, as well as lower selling, general and administrative (“SG&A”) expenses. The increase was partially offset by higher acquired in-process research and development (“IPR&D”) expenses and an IPR&D impairment charge related to assets acquired as part of the MYR GmbH (“MYR”) acquisition.

  • Non-GAAP diluted EPS of $1.86 in the fourth quarter 2025 compared to $1.90 in the same period in 2024. The decrease was primarily driven by higher acquired IPR&D expenses, partially offset by higher product sales and lower SG&A expenses.

  • As of December 31, 2025, Gilead had $10.6 billion of cash, cash equivalents and marketable debt securities compared to $10.0 billion as of December 31, 2024.

  • During the fourth quarter 2025, Gilead generated $3.3 billion in operating cash flow.

  • During the fourth quarter 2025, Gilead paid dividends of $1.0 billion and repurchased $230 million of common stock.

Fourth Quarter 2025 Product Sales

Total fourth quarter 2025 product sales increased 5% to $7.9 billion compared to the same period in 2024. Total fourth quarter 2025 product sales excluding Veklury increased 7% to $7.7 billion compared to the same period in 2024, primarily due to higher sales of HIV and Liver Disease products.

HIV product sales increased 6% to $5.8 billion in the fourth quarter 2025 compared to the same period in 2024, primarily driven by higher demand for HIV prevention and treatment.

  • Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 5% to $4.0 billion in the fourth quarter 2025 compared to the same period in 2024, primarily driven by higher demand and favorable inventory dynamics, partially offset by lower average realized price.
  • Descovy® (FTC 200mg/TAF 25mg) sales increased 33% to $819 million in the fourth quarter 2025 compared to the same period in 2024, primarily driven by higher average realized price and higher demand for HIV prevention.

The Liver Disease portfolio sales increased 17% to $844 million in the fourth quarter 2025 compared to the same period in 2024, primarily driven by higher demand for Livdelzi® (seladelpar).

Veklury sales decreased 37% to $212 millionin the fourth quarter 2025 compared to the same period in 2024, primarily driven by lower rates of COVID-19-related hospitalizations.

Cell Therapy product sales decreased 6% to $458 million in the fourth quarter 2025 compared to the same period in 2024, reflecting ongoing competitive headwinds.

  • Yescarta® (axicabtagene ciloleucel) sales decreased 6% to $368 million in the fourth quarter 2025 compared to the same period in 2024, primarily driven by in- and out-of-class competition.
  • Tecartus® (brexucabtagene autoleucel) sales decreased 9% to $90 million in the fourth quarter 2025 compared to the same period in 2024, primarily driven by in-class competition.

Trodelvy® (sacituzumab govitecan-hziy) sales increased 8% to $384 million in the fourth quarter 2025 compared to the same period in 2024, primarily driven by higher demand in breast cancer treatment.

Fourth Quarter 2025 Product Gross Margin, Operating Expenses and Effective Tax Rate

  • Product gross margin remained relatively flat at 79.5% in the fourth quarter 2025 compared to 79.0% in the same period in 2024. Non-GAAP product gross margin was 86.8% in the fourth quarter 2025 compared to 86.7% in the same period in 2024.

  • Research and development (“R&D”) expenses and non-GAAP R&D expenses were $1.6 billion in the fourth quarter 2025 and remained relatively flat compared to the same period in 2024.

  • Acquired IPR&D expenses were $539 million in the fourth quarter 2025, primarily related to our acquisition of Interius BioTherapeutics, Inc. (“Interius”) and ongoing collaboration with Shenzhen Pregene Biopharma Co., Ltd. (“Pregene”).

  • SG&A expenses were $1.8 billion in the fourth quarter 2025 compared to $1.9 billion in the same period in 2024, decreasing primarily due to lower expenses related to legal matters and corporate initiatives, partially offset by donations of equity securities made to the Gilead Foundation. Non-GAAP SG&A expenses were $1.7 billion in the fourth quarter 2025 compared to $1.9 billion in the same period in 2024, primarily due to lower expenses related to legal matters and corporate initiatives.

  • The effective tax rate (“ETR”) was (5.0)% in the fourth quarter 2025 compared to 17.8% in the same period in 2024, primarily driven by a tax benefit from a settlement with a tax authority related to a prior year legal entity restructuring and a tax benefit from the IPR&D impairment charge related to assets acquired as part of the MYR acquisition. The non-GAAP ETR was 20.5% in the fourth quarter 2025 compared to 19.2% in the same period in 2024.

Full Year 2025 Financial Results

  • Total full year 2025 revenues increased 2% to $29.4 billion compared to 2024, broken down as follows:

    • Total full year 2025 product sales increased 1% to $28.9 billion compared to 2024, primarily driven by higher sales of HIV and Liver Disease products, partially offset by lower sales of Veklury.

    • Total full year 2025 royalty, contract and other revenues increased by approximately $383 million compared to 2024, primarily driven by revenue related to a previous sale of intellectual property not expected to reoccur.

  • Diluted EPS was $6.78 in the full year 2025 compared to $0.38 in 2024. The increase was primarily driven by lower acquired IPR&D expenses, lower IPR&D impairments, higher net unrealized gains on equity investments, higher revenues and lower SG&A expenses, partially offset by higher tax expense.

  • Non-GAAP diluted EPS was $8.15 in the full year 2025 compared to $4.62 in 2024. The increase was primarily driven by lower acquired IPR&D expenses, higher revenues, and lower SG&A expenses.

Full Year 2025 Product Sales

Total full year 2025 product sales increased 1% to $28.9 billion compared to 2024. Total full year 2025 product sales excluding Veklury increased 4% to $28.0 billion compared to 2024, primarily due to higher sales of HIV and Liver Disease products.

HIV product sales increased 6% to $20.8 billion in the full year 2025 compared to 2024, primarily driven by higher demand for HIV treatment and prevention.

  • Biktarvy sales increased 7% to $14.3 billion in the full year 2025 compared to 2024, primarily driven by higher demand, partially offset by lower average realized price.
  • Descovy sales increased 31% to $2.8 billion in the full year 2025 compared to 2024, primarily driven by higher demand and average realized price.

The Liver Disease portfolio sales increased 6% to $3.2 billion in the full year 2025 compared to 2024, primarily driven by higher demand for Livdelzi and products for chronic hepatitis B virus (“HBV”) and chronic hepatitis delta virus (“HDV”), partially offset by lower average realized price in products for chronic hepatitis C virus (“HCV”).

Veklury sales decreased 49% to $911 millionin the full year 2025 compared to 2024, primarily driven by lower COVID-19-related hospitalizations.

Cell Therapy product sales decreased 7% to $1.8 billion in the full year 2025 compared to 2024, reflecting ongoing competitive headwinds.

  • Yescarta sales decreased 5% to $1.5 billion in the full year 2025 compared to 2024, primarily driven by in- and out-of-class competition.
  • Tecartus sales decreased 15% to $344 million in the full year 2025 compared to 2024, primarily driven by in-class competition.

Trodelvy sales increased 6% to $1.4 billion in the full year 2025 compared to 2024, primarily driven by higher demand in breast cancer treatment, partially offset by the indication withdrawal in bladder cancer treatment.

Full Year 2025 Product Gross Margin, Operating Expenses and Effective Tax Rate

  • Product gross margin remained relatively flat at 78.4% in the full year 2025 compared to 78.2% in 2024. Non-GAAP product gross margin was 86.4% in the full year 2025 compared to 86.2% in 2024.

  • R&D expenses were $5.8 billion in the full year 2025 compared to $5.9 billion in 2024, decreasing primarily due to lower acquisition-related integration expenses and restructuring costs, as well as lower study-related and clinical manufacturing expenses. Non-GAAP R&D expenses were $5.7 billion in the full year 2025, decreasing slightly compared to 2024 due to lower study-related and clinical manufacturing expenses.

  • Acquired IPR&D expenses were $1.0 billion in the full year 2025, primarily related to the acquisition of Interius and collaborations with LEO Pharma A/S and Pregene.

  • SG&A expenses were $5.8 billion in the full year 2025 compared to $6.1 billion in 2024, decreasing primarily due to lower corporate, legal, acquisition-related integration and restructuring expenses, partially offset by higher HIV promotional expenses and donations of equity securities made to the Gilead Foundation. Non-GAAP SG&A expenses were $5.6 billion in the full year 2025 compared to $5.9 billion in 2024, decreasing primarily due to lower expenses related to corporate initiatives and legal matters, partially offset by higher HIV promotional expenses.

  • The ETR was 13.1% in the full year 2025 compared to 30.5% in 2024, primarily driven by the impact of the prior year non-deductible acquired IPR&D charge for the acquisition of CymaBay Therapeutics, Inc. (“CymaBay”), partially offset by the tax impact of the prior year higher IPR&D impairment charges. The non-GAAP ETR was 18.3% in the full year 2025 compared to 25.9% in 2024, primarily driven by the prior year non-deductible acquired IPR&D charge for the acquisition of CymaBay.

Guidance and Outlook

For the full year 2026, Gilead expects:

(in millions, except per share amounts)

 

February 10, 2026 Guidance

 

Low End

High End

Product sales

 

$

29,600

 

$

30,000

 

Product sales excluding Veklury

 

$

29,000

 

$

29,400

 

Veklury

 

$

600

 

$

600

 

Diluted EPS

 

$

6.75

 

$

7.15

 

Non-GAAP diluted EPS

 

$

8.45

 

$

8.85

 

Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.

Key Updates Since Our Last Quarterly Release

Virology

  • Announced positive topline Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials, evaluating our investigational daily oral single-tablet regimen of bictegravir 75mg and lenacapavir 50mg (“BIC/LEN”) for virologically suppressed adults with HIV. BIC/LEN met its primary endpoints demonstrating non-inferiority to baseline multi-tablet antiviral regimens (ARTISTRY-1) and Biktarvy (ARTISTRY-2).

  • Exercised option to license investigational herpes simplex virus helicase-primase inhibitor programs ABI-1179 and ABI-5366 from Assembly Biosciences, Inc. (“Assembly”).

  • Announced the first delivery of lenacapavir for PrEP in sub-Saharan African countries Eswatini and Zambia through the U.S. President’s Emergency Plan for AIDS Relief.

Oncology

  • Announced that the Phase 3 ASCENT-07 study evaluating the investigational use of Trodelvy versus chemotherapy in first-line post-endocrine HR+/HER2- metastatic breast cancer did not meet its primary endpoint of progression-free survival as assessed by Blinded Independent Central Review. Overall survival, a secondary endpoint, was not mature at the time of the primary analysis, however, a favorable early trend compared to chemotherapy was observed in the Trodelvy arm. In addition, no new safety signals were identified in this patient population. The results from this study were presented at the 2025 San Antonio Breast Cancer Symposium.

  • Announced the discontinuation of the Phase 3 STAR-221 study, in partnership with Arcus Biosciences, Inc. (“Arcus”), evaluating the anti-TIGIT antibody domvanalimab (“dom”) plus zimberelimab (“zim”) and chemotherapy in first-line HER2- advanced gastric and esophageal cancers. The decision was based on the recommendation of the Independent Data Monitoring Committee, following review of data from a pre-specified interim analysis. Additionally, Gilead and Arcus will discontinue the Phase 2 EDGE-Gastric study evaluating dom and zim regimens in upper gastrointestinal cancers. Dom and zim are investigational products and are not approved anywhere globally.

Cell Therapy

  • Announced a new label update for Yescarta that removes a limitation around Primary Central Nervous System Lymphoma, an ultra-rare cancer affecting a highly vulnerable patient population. Yescarta is the only CAR-T therapy in relapsed or refractory large B-cell lymphoma (“R/R LBCL”) to have this limitation removed.

  • Presented new positive data, with our partner Arcellx, Inc. (“Arcellx”), from the pivotal Phase 2 iMMagine-1 trial evaluating the investigational CAR T-cell therapy anitocabtagene autoleucel in 4L+ R/R multiple myeloma at the 2025 American Society of Hematology (“ASH”).

  • Presented initial Phase 1 data for KITE-753 and KITE-363, evaluating two investigational bicistronic CAR T-cell therapies in patients with R/R LBCL at ASH 2025.

  • Presented a new analysis of Yescarta from the Phase 3 ZUMA-7 and Phase 2 ALYCANTE study in patients with R/R LBCL at ASH 2025. The data demonstrated consistent benefits of Yescarta among patients with R/R LBCL, including those ineligible for previous standard of care chemotherapy and stem cell transplant.

Inflammation

  • Presented new long-term data from the Phase 3 ASSURE study for Livdelzi, which reinforce the safety and efficacy of Livdelzi for people living with primary biliary cholangitis over 3 years, including data on switching from obeticholic acid. The data were presented at the American Association for the Study of Liver Diseases meeting.

Corporate

  • The Board declared a quarterly dividend of $0.82 per share of common stock for the first quarter of 2026. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval.

  • Appointed Keeley Cain Wettan as Executive Vice President, General Counsel, Legal and Compliance.

  • Announced an agreement with the U.S. government to lower the cost of medicines for Americans, reinforcing a commitment to U.S.-based innovation, affordability and global health leadership.

Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

Conference Call

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

Non-GAAP Financial Information

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with such exclusions as well as changes in tax-related laws and guidelines, transfers of intangible assets between certain legal entities, and legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation.Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2026 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact from Medicare Part D pricing reform in the Inflation Reduction Act, the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, Arcus, Assembly and the U.S. government; the risk that Gilead’s U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving anitocabtagene autoleucel, axicabtagene ciloleucel, bictegravir, domvanalimab, lenacapavir, sacituzumab govitecan-hziy, seladelpar, zimberelimab, ABI-1179, ABI-5366, KITE-753 and KITE-363 (such as ALYCANTE, ARTISTRY-1, ARTISTRY-2, ASCENT-07, ASSURE, EDGE-Gastric, iMMagine-1, STAR-221 and ZUMA-7), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies and may therefore be reluctant to prescribe the products; Gilead’s ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter and full year ended December 31, 2025 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Additional information is available on our Investor Relations website, https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D expenses is expected to be made available on the Quarterly Results page within the first ten (10) days after the end of each quarter.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. Other trademarks and trade names are the property of their respective owners.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions, except per share amounts)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Revenues:

 

 

 

 

 

 

 

 

Product sales

 

$

7,903

 

 

$

7,536

 

 

$

28,915

 

 

$

28,610

 

Royalty, contract and other revenues

 

 

22

 

 

 

33

 

 

 

527

 

 

 

144

 

Total revenues

 

 

7,925

 

 

 

7,569

 

 

 

29,443

 

 

 

28,754

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

1,623

 

 

 

1,581

 

 

 

6,234

 

 

 

6,251

 

Research and development expenses

 

 

1,584

 

 

 

1,641

 

 

 

5,799

 

 

 

5,907

 

Acquired in-process research and development expenses

 

 

539

 

 

 

(11

)

 

 

1,024

 

 

 

4,663

 

In-process research and development impairments

 

 

400

 

 

 

 

 

 

590

 

 

 

4,180

 

Selling, general and administrative expenses

 

 

1,794

 

 

 

1,906

 

 

 

5,774

 

 

 

6,091

 

Total costs and expenses

 

 

5,940

 

 

 

5,118

 

 

 

19,421

 

 

 

27,092

 

Operating income

 

 

1,984

 

 

 

2,451

 

 

 

10,022

 

 

 

1,662

 

Interest expense

 

 

255

 

 

 

248

 

 

 

1,024

 

 

 

977

 

Other (income) expense, net

 

 

(349

)

 

 

35

 

 

 

(798

)

 

 

(6

)

Income before income taxes

 

 

2,078

 

 

 

2,168

 

 

 

9,796

 

 

 

690

 

Income tax (benefit) expense

 

 

(105

)

 

 

385

 

 

 

1,286

 

 

 

211

 

Net income

 

 

2,183

 

 

 

1,783

 

 

 

8,510

 

 

 

480

 

Net income attributable to noncontrolling interest

 

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to Gilead

 

$

2,183

 

 

$

1,783

 

 

$

8,510

 

 

$

480

 

 

 

 

 

 

 

 

 

 

Basic earnings per share attributable to Gilead

 

$

1.76

 

 

$

1.43

 

 

$

6.84

 

 

$

0.38

 

Diluted earnings per share attributable to Gilead

 

$

1.74

 

 

$

1.42

 

 

$

6.78

 

 

$

0.38

 

 

 

 

 

 

 

 

 

 

Shares used in basic earnings per share attributable to Gilead calculation

 

 

1,242

 

 

 

1,248

 

 

 

1,244

 

 

 

1,247

 

Shares used in diluted earnings per share attributable to Gilead calculation

 

 

1,253

 

 

 

1,259

 

 

 

1,255

 

 

 

1,255

 

 

 

 

 

 

 

 

 

 

Supplemental Information:

 

 

 

 

 

 

 

 

Cash dividends declared per share

 

$

0.79

 

 

$

0.77

 

 

$

3.16

 

 

$

3.08

 

Product gross margin

 

 

79.5

%

 

 

79.0

%

 

 

78.4

%

 

 

78.2

%

Research and development expenses as a % of revenues

 

 

20.0

%

 

 

21.7

%

 

 

19.7

%

 

 

20.5

%

Selling, general and administrative expenses as a % of revenues

 

 

22.6

%

 

 

25.2

%

 

 

19.6

%

 

 

21.2

%

Operating margin

 

 

25.0

%

 

 

32.4

%

 

 

34.0

%

 

 

5.8

%

Effective tax rate

 

 

(5.0

)%

 

 

17.8

%

 

 

13.1

%

 

 

30.5

%

GILEAD SCIENCES, INC.

TOTAL REVENUE SUMMARY

(unaudited)

 

 

Three Months Ended

 

 

 

Twelve Months Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

(in millions, except percentages)

 

 

2025

 

 

2024

 

Change

 

 

2025

 

 

2024

 

Change

Product sales:

 

 

 

 

 

 

 

 

 

 

 

 

HIV

 

$

5,801

 

$

5,452

 

6

%

 

$

20,752

 

$

19,612

 

6

%

Liver Disease

 

 

844

 

 

719

 

17

%

 

 

3,217

 

 

3,021

 

6

%

Oncology

 

 

842

 

 

843

 

%

 

 

3,236

 

 

3,289

 

(2

)%

Other

 

 

205

 

 

184

 

11

%

 

 

799

 

 

889

 

(10

)%

Total product sales excluding Veklury

 

 

7,691

 

 

7,198

 

7

%

 

 

28,004

 

 

26,811

 

4

%

Veklury

 

 

212

 

 

337

 

(37

)%

 

 

911

 

 

1,799

 

(49

)%

Total product sales

 

 

7,903

 

 

7,536

 

5

%

 

 

28,915

 

 

28,610

 

1

%

Royalty, contract and other revenues

 

 

22

 

 

33

 

(35

)%

 

 

527

 

 

144

 

NM

 

Total revenues

 

$

7,925

 

$

7,569

 

5

%

 

$

29,443

 

$

28,754

 

2

%

GILEAD SCIENCES, INC.

NON-GAAP FINANCIAL INFORMATION(1)

(unaudited)

 

 

Three Months Ended

 

 

 

Twelve Months Ended

 

 

 

 

December 31,

 

 

 

December 31,

 

 

(in millions, except percentages)

 

2025

 

 

 

2024

 

 

Change

 

 

2025

 

 

 

2024

 

 

Change

Non-GAAP:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

1,044

 

 

$

1,002

 

 

4

%

 

$

3,919

 

 

$

3,936

 

 

%

Research and development expenses

 

$

1,565

 

 

$

1,612

 

 

(3

)%

 

$

5,687

 

 

$

5,732

 

 

(1

)%

Acquired IPR&D expenses

 

$

539

 

 

$

(11

)

 

NM

 

 

$

1,024

 

 

$

4,663

 

 

(78

)%

Selling, general and administrative expenses

 

$

1,688

 

 

$

1,852

 

 

(9

)%

 

$

5,619

 

 

$

5,903

 

 

(5

)%

Other (income) expense, net

 

$

(97

)

 

$

(91

)

 

7

%

 

$

(348

)

 

$

(279

)

 

24

%

Diluted earnings per share attributable to Gilead

 

$

1.86

 

 

$

1.90

 

 

(2

)%

 

$

8.15

 

 

$

4.62

 

 

77

%

Shares used in non-GAAP diluted earnings per share attributable to Gilead calculation

 

 

1,253

 

 

 

1,259

 

 

%

 

 

1,255

 

 

 

1,255

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Product gross margin

 

 

86.8

%

 

 

86.7

%

 

9 bps

 

 

 

86.4

%

 

 

86.2

%

 

20 bps

 

Research and development expenses as a % of revenues

 

 

19.7

%

 

 

21.3

%

 

-155 bps

 

 

 

19.3

%

 

 

19.9

%

 

-62 bps

 

Selling, general and administrative expenses as a % of revenues

 

 

21.3

%

 

 

24.5

%

 

-317 bps

 

 

 

19.1

%

 

 

20.5

%

 

-144 bps

 

Operating margin

 

 

39.0

%

 

 

41.1

%

 

-217 bps

 

 

 

44.8

%

 

 

29.6

%

 

NM

 

Effective tax rate

 

 

20.5

%

 

 

19.2

%

 

135 bps

 

 

 

18.3

%

 

 

25.9

%

 

-765 bps

 

 

 

 

NM

– Not Meaningful

(1)

Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions, except percentages and per share amounts)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Cost of goods sold reconciliation:

 

 

 

 

 

 

 

 

GAAP cost of goods sold

 

$

1,623

 

 

$

1,581

 

 

$

6,234

 

 

$

6,251

 

Acquisition-related – amortization(1)

 

 

(576

)

 

 

(579

)

 

 

(2,310

)

 

 

(2,316

)

Restructuring

 

 

(4

)

 

 

 

 

 

(4

)

 

 

 

Non-GAAP cost of goods sold

 

$

1,044

 

 

$

1,002

 

 

$

3,919

 

 

$

3,936

 

 

 

 

 

 

 

 

 

 

Product gross margin reconciliation:

 

 

 

 

 

 

 

 

GAAP product gross margin

 

 

79.5

%

 

 

79.0

%

 

 

78.4

%

 

 

78.2

%

Acquisition-related – amortization(1)

 

 

7.3

%

 

 

7.7

%

 

 

8.0

%

 

 

8.1

%

Restructuring

 

 

%

 

 

%

 

 

%

 

 

%

Non-GAAP product gross margin

 

 

86.8

%

 

 

86.7

%

 

 

86.4

%

 

 

86.2

%

 

 

 

 

 

 

 

 

 

Research and development expenses reconciliation:

 

 

 

 

 

 

 

 

GAAP research and development expenses

 

$

1,584

 

 

$

1,641

 

 

$

5,799

 

 

$

5,907

 

Acquisition-related – other costs(2)

 

 

(3

)

 

 

 

 

 

(43

)

 

 

(78

)

Restructuring

 

 

(16

)

 

 

(30

)

 

 

(69

)

 

 

(98

)

Non-GAAP research and development expenses

 

$

1,565

 

 

$

1,612

 

 

$

5,687

 

 

$

5,732

 

 

 

 

 

 

 

 

 

 

IPR&D impairment reconciliation:

 

 

 

 

 

 

 

 

GAAP IPR&D impairment

 

$

400

 

 

$

 

 

$

590

 

 

$

4,180

 

IPR&D impairment

 

 

(400

)

 

 

 

 

 

(590

)

 

 

(4,180

)

Non-GAAP IPR&D impairment

 

$

 

 

$

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses reconciliation:

 

 

 

 

 

 

 

 

GAAP selling, general and administrative expenses

 

$

1,794

 

 

$

1,906

 

 

$

5,774

 

 

$

6,091

 

Acquisition-related – other costs(2)

 

 

 

 

 

(8

)

 

 

 

 

 

(97

)

Restructuring

 

 

(17

)

 

 

(46

)

 

 

(65

)

 

 

(91

)

Other(3)

 

 

(89

)

 

 

 

 

 

(89

)

 

 

 

Non-GAAP selling, general and administrative expenses

 

$

1,688

 

 

$

1,852

 

 

$

5,619

 

 

$

5,903

 

 

 

 

 

 

 

 

 

 

Operating income reconciliation:

 

 

 

 

 

 

 

 

GAAP operating income

 

$

1,984

 

 

$

2,451

 

 

$

10,022

 

 

$

1,662

 

Acquisition-related – amortization(1)

 

 

576

 

 

 

579

 

 

 

2,310

 

 

 

2,316

 

Acquisition-related – other costs(2)

 

 

3

 

 

 

8

 

 

 

43

 

 

 

174

 

Restructuring

 

 

37

 

 

 

76

 

 

 

138

 

 

 

188

 

IPR&D impairment

 

 

400

 

 

 

 

 

 

590

 

 

 

4,180

 

Other(3)

 

 

89

 

 

 

 

 

 

89

 

 

 

 

Non-GAAP operating income

 

$

3,089

 

 

$

3,114

 

 

$

13,193

 

 

$

8,520

 

 

 

 

 

 

 

 

 

 

Operating margin reconciliation:

 

 

 

 

 

 

 

 

GAAP operating margin

 

 

25.0

%

 

 

32.4

%

 

 

34.0

%

 

 

5.8

%

Acquisition-related – amortization(1)

 

 

7.3

%

 

 

7.6

%

 

 

7.8

%

 

 

8.1

%

Acquisition-related – other costs(2)

 

 

%

 

 

0.1

%

 

 

0.1

%

 

 

0.6

%

Restructuring

 

 

0.5

%

 

 

1.0

%

 

 

0.5

%

 

 

0.7

%

IPR&D impairment

 

 

5.0

%

 

 

%

 

 

2.0

%

 

 

14.5

%

Other(3)

 

 

1.1

%

 

 

%

 

 

0.3

%

 

 

%

Non-GAAP operating margin

 

 

39.0

%

 

 

41.1

%

 

 

44.8

%

 

 

29.6

%

 

 

 

 

 

 

 

 

 

Other (income) expense, net reconciliation:

 

 

 

 

 

 

 

 

GAAP other (income) expense, net

 

$

(349

)

 

$

35

 

 

$

(798

)

 

$

(6

)

Gain (loss) from equity securities, net

 

 

252

 

 

 

(126

)

 

 

451

 

 

 

(274

)

Non-GAAP other (income) expense, net

 

$

(97

)

 

$

(91

)

 

$

(348

)

 

$

(279

)

 

 

 

 

 

 

 

 

 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION – (Continued)

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions, except percentages and per share amounts)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Income before income taxes reconciliation:

 

 

 

 

 

 

 

 

GAAP income before income taxes

 

$

2,078

 

 

$

2,168

 

 

$

9,796

 

 

$

690

 

Acquisition-related – amortization(1)

 

 

576

 

 

 

579

 

 

 

2,310

 

 

 

2,316

 

Acquisition-related – other costs(2)

 

 

3

 

 

 

8

 

 

 

43

 

 

 

174

 

Restructuring

 

 

37

 

 

 

76

 

 

 

138

 

 

 

188

 

IPR&D impairment

 

 

400

 

 

 

 

 

 

590

 

 

 

4,180

 

(Gain) loss from equity securities, net

 

 

(252

)

 

 

126

 

 

 

(451

)

 

 

274

 

Other(3)

 

 

89

 

 

 

 

 

 

89

 

 

 

 

Non-GAAP income before income taxes

 

$

2,930

 

 

$

2,956

 

 

$

12,517

 

 

$

7,822

 

 

 

 

 

 

 

 

 

 

Income tax (benefit) expense reconciliation:

 

 

 

 

 

 

 

 

GAAP income tax (benefit) expense

 

$

(105

)

 

$

385

 

 

$

1,286

 

 

$

211

 

Income tax effect of non-GAAP adjustments:

 

 

 

 

 

 

 

 

Acquisition-related – amortization(1)

 

 

118

 

 

 

121

 

 

 

478

 

 

 

484

 

Acquisition-related – other costs(2)

 

 

 

 

 

2

 

 

 

 

 

 

41

 

Restructuring

 

 

7

 

 

 

16

 

 

 

25

 

 

 

37

 

IPR&D impairment

 

 

87

 

 

 

 

 

 

137

 

 

 

1,051

 

Loss (gain) from equity securities, net

 

 

14

 

 

 

13

 

 

 

(20

)

 

 

(39

)

Discrete and related tax charges(4)

 

 

454

 

 

 

29

 

 

 

353

 

 

 

243

 

Other(3)

 

 

27

 

 

 

 

 

 

27

 

 

 

 

Non-GAAP income tax expense

 

$

601

 

 

$

566

 

 

$

2,287

 

 

$

2,028

 

 

 

 

 

 

 

 

 

 

Effective tax rate reconciliation:

 

 

 

 

 

 

 

 

GAAP effective tax rate

 

 

(5.0

)%

 

 

17.8

%

 

 

13.1

%

 

 

30.5

%

Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4)

 

 

25.6

%

 

 

1.4

%

 

 

5.1

%

 

 

(4.6

)%

Non-GAAP effective tax rate

 

 

20.5

%

 

 

19.2

%

 

 

18.3

%

 

 

25.9

%

 

 

 

 

 

 

 

 

 

Net income attributable to Gilead reconciliation:

 

 

 

 

 

 

 

 

GAAP net income attributable to Gilead

 

$

2,183

 

 

$

1,783

 

 

$

8,510

 

 

$

480

 

Acquisition-related – amortization(1)

 

 

458

 

 

 

458

 

 

 

1,832

 

 

 

1,832

 

Acquisition-related – other costs(2)

 

 

3

 

 

 

6

 

 

 

43

 

 

 

134

 

Restructuring

 

 

30

 

 

 

59

 

 

 

113

 

 

 

151

 

IPR&D impairment

 

 

313

 

 

 

 

 

 

453

 

 

 

3,129

 

(Gain) loss from equity securities, net

 

 

(266

)

 

 

113

 

 

 

(431

)

 

 

313

 

Discrete and related tax charges(4)

 

 

(454

)

 

 

(29

)

 

 

(353

)

 

 

(243

)

Other(3)

 

 

63

 

 

 

 

 

 

63

 

 

 

 

Non-GAAP net income attributable to Gilead

 

$

2,329

 

 

$

2,390

 

 

$

10,230

 

 

$

5,795

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share reconciliation:

 

 

 

 

 

 

 

 

GAAP diluted earnings per share

 

$

1.74

 

 

$

1.42

 

 

$

6.78

 

 

$

0.38

 

Acquisition-related – amortization(1)

 

 

0.37

 

 

 

0.36

 

 

 

1.46

 

 

 

1.46

 

Acquisition-related – other costs(2)

 

 

 

 

 

 

 

 

0.03

 

 

 

0.11

 

Restructuring

 

 

0.02

 

 

 

0.05

 

 

 

0.09

 

 

 

0.12

 

IPR&D impairment

 

 

0.25

 

 

 

 

 

 

0.36

 

 

 

2.49

 

(Gain) loss from equity securities, net

 

 

(0.21

)

 

 

0.09

 

 

 

(0.34

)

 

 

0.25

 

Discrete and related tax charges(4)

 

 

(0.36

)

 

 

(0.02

)

 

 

(0.28

)

 

 

(0.19

)

Other(3)

 

 

0.05

 

 

 

 

 

 

0.05

 

 

 

 

Non-GAAP diluted earnings per share

 

$

1.86

 

 

$

1.90

 

 

$

8.15

 

 

$

4.62

 

 

 

 

 

 

 

 

 

 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION – (Continued)

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions, except percentages and per share amounts)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Non-GAAP adjustment summary:

 

 

 

 

 

 

 

 

Cost of goods sold adjustments

 

$

579

 

 

$

579

 

 

$

2,314

 

 

$

2,315

 

Research and development expenses adjustments

 

 

19

 

 

 

29

 

 

 

112

 

 

 

176

 

IPR&D impairment adjustments

 

 

400

 

 

 

 

 

 

590

 

 

 

4,180

 

Selling, general and administrative expenses adjustments

 

 

106

 

 

 

54

 

 

 

155

 

 

 

188

 

Total non-GAAP adjustments to costs and expenses

 

 

1,104

 

 

 

663

 

 

 

3,171

 

 

 

6,858

 

Other (income) expense, net, adjustments

 

 

(252

)

 

 

126

 

 

 

(451

)

 

 

274

 

Total non-GAAP adjustments before income taxes

 

 

852

 

 

 

789

 

 

 

2,720

 

 

 

7,132

 

Income tax effect of non-GAAP adjustments above

 

 

(252

)

 

 

(152

)

 

 

(647

)

 

 

(1,574

)

Discrete and related tax charges(4)

 

 

(454

)

 

 

(29

)

 

 

(353

)

 

 

(243

)

Total non-GAAP adjustments to net income attributable to Gilead

 

$

146

 

 

$

607

 

 

$

1,719

 

 

$

5,315

 

 

 

 

(1)

Relates to amortization of acquired intangibles.

(2)

Adjustments include integration expenses and contingent consideration fair value adjustments associated with Gilead’s recent acquisitions.

(3)

Adjustments include donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the fourth quarter of 2025.

(4)

Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)

(unaudited)

 

 

 

(in millions, except percentages and per share amounts)

 

Provided

February 10, 2026

Projected product gross margin GAAP to non-GAAP reconciliation:

 

 

GAAP projected product gross margin

 

~ 79.0%

Acquisition-related expenses

 

~ 8.0%

Non-GAAP projected product gross margin

 

~ 87.0%

 

 

 

Projected operating income GAAP to non-GAAP reconciliation:

 

 

GAAP projected operating income

 

$11,400 – $11,900

Acquisition-related and restructuring expenses

 

~ 2,400

Non-GAAP projected operating income

 

$13,800 – $14,300

 

 

 

Projected effective tax rate GAAP to non-GAAP reconciliation:

 

 

GAAP projected effective tax rate

 

~ 21%

Income tax effect of above non-GAAP adjustments, and discrete and related tax adjustments

 

(~ 1%)

Non-GAAP projected effective tax rate

 

~ 20%

 

 

 

Projected diluted EPS GAAP to non-GAAP reconciliation:

 

 

GAAP projected diluted EPS

 

$6.75 – $7.15

Acquisition-related and restructuring expenses, and discrete and related tax adjustments

 

~ 1.70

Non-GAAP projected diluted EPS

 

$8.45 – $8.85

 

 

 

(1)

Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

 

December 31,

 

December 31,

(in millions)

 

 

2025

 

 

2024

Assets

 

 

 

 

Cash, cash equivalents and marketable debt securities

 

$

10,605

 

$

9,991

Accounts receivable, net

 

 

4,913

 

 

4,420

Inventories(1)

 

 

4,368

 

 

3,589

Property, plant and equipment, net

 

 

5,606

 

 

5,414

Intangible assets, net

 

 

16,978

 

 

19,948

Goodwill

 

 

8,314

 

 

8,314

Other assets

 

 

8,239

 

 

7,319

Total assets

 

$

59,023

 

$

58,995

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities

 

$

11,813

 

$

12,004

Long-term liabilities

 

 

24,592

 

 

27,744

Stockholders’ equity(2)

 

 

22,618

 

 

19,246

Total liabilities and stockholders’ equity

 

$

59,023

 

$

58,995

 

 

 

(1)

Includes current and long-term inventories, which are disclosed separately in the notes to our financial statements in Form 10-K and Form 10-Q.

(2)

As of December 31, 2025 and December 31, 2024, there were 1,241 and 1,246 shares of common stock issued and outstanding, respectively.

GILEAD SCIENCES, INC.

SELECTED CASH FLOW INFORMATION

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Net cash provided by operating activities

 

$

3,326

 

 

$

2,975

 

 

$

10,019

 

 

$

10,828

 

Net cash used in investing activities

 

 

(1,835

)

 

 

(225

)

 

 

(4,793

)

 

 

(3,449

)

Net cash (used in) provided by financing activities

 

 

(1,263

)

 

 

2,260

 

 

 

(7,745

)

 

 

(3,433

)

Effect of exchange rate changes on cash and cash equivalents

 

 

5

 

 

 

(55

)

 

 

92

 

 

 

(40

)

Net change in cash and cash equivalents

 

 

233

 

 

 

4,954

 

 

 

(2,428

)

 

 

3,906

 

Cash and cash equivalents at beginning of period

 

 

7,330

 

 

 

5,037

 

 

 

9,991

 

 

 

6,085

 

Cash and cash equivalents at end of period

 

$

7,564

 

 

$

9,991

 

 

$

7,564

 

 

$

9,991

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Net cash provided by operating activities

 

$

3,326

 

 

$

2,975

 

 

$

10,019

 

 

$

10,828

 

Purchases of property, plant and equipment

 

 

(205

)

 

 

(147

)

 

 

(563

)

 

 

(523

)

Free cash flow(1)

 

$

3,121

 

 

$

2,828

 

 

$

9,456

 

 

$

10,305

 

 

 

 

(1)

Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions)

 

 

2025

 

 

2024

 

 

2025

 

 

2024

HIV

 

 

 

 

 

 

 

 

Biktarvy – U.S.

 

$

3,255

 

$

3,129

 

$

11,467

 

$

10,855

Biktarvy – Europe

 

 

446

 

 

400

 

 

1,676

 

 

1,509

Biktarvy – Rest of World

 

 

268

 

 

246

 

 

1,190

 

 

1,060

 

 

 

3,968

 

 

3,774

 

 

14,334

 

 

13,423

 

 

 

 

 

 

 

 

 

Descovy – U.S.

 

 

768

 

 

563

 

 

2,559

 

 

1,902

Descovy – Europe

 

 

26

 

 

25

 

 

93

 

 

100

Descovy – Rest of World

 

 

25

 

 

28

 

 

105

 

 

110

 

 

 

819

 

 

616

 

 

2,758

 

 

2,113

 

 

 

 

 

 

 

 

 

Genvoya – U.S.

 

 

331

 

 

410

 

 

1,281

 

 

1,498

Genvoya – Europe

 

 

34

 

 

42

 

 

148

 

 

180

Genvoya – Rest of World

 

 

15

 

 

18

 

 

69

 

 

84

 

 

 

380

 

 

470

 

 

1,498

 

 

1,762

 

 

 

 

 

 

 

 

 

Odefsey – U.S.

 

 

238

 

 

252

 

 

881

 

 

957

Odefsey – Europe

 

 

62

 

 

74

 

 

246

 

 

290

Odefsey – Rest of World

 

 

10

 

 

11

 

 

40

 

 

41

 

 

 

310

 

 

336

 

 

1,167

 

 

1,288

 

 

 

 

 

 

 

 

 

Symtuza – Revenue share(1) – U.S.

 

 

98

 

 

112

 

 

363

 

 

450

Symtuza – Revenue share(1) – Europe

 

 

32

 

 

30

 

 

120

 

 

130

Symtuza – Revenue share(1) – Rest of World

 

 

3

 

 

3

 

 

12

 

 

12

 

 

 

134

 

 

144

 

 

495

 

 

592

 

 

 

 

 

 

 

 

 

Other HIV(2) – U.S.

 

 

154

 

 

67

 

 

352

 

 

257

Other HIV(2) – Europe

 

 

24

 

 

33

 

 

109

 

 

129

Other HIV(2) – Rest of World

 

 

12

 

 

11

 

 

40

 

 

48

 

 

 

190

 

 

111

 

 

500

 

 

434

 

 

 

 

 

 

 

 

 

Total HIV – U.S.

 

 

4,845

 

 

4,532

 

 

16,904

 

 

15,918

Total HIV – Europe

 

 

624

 

 

603

 

 

2,392

 

 

2,339

Total HIV – Rest of World

 

 

332

 

 

317

 

 

1,456

 

 

1,355

 

 

 

5,801

 

 

5,452

 

 

20,752

 

 

19,612

Liver Disease

 

 

 

 

 

 

 

 

Sofosbuvir / Velpatasvir(3) – U.S.

 

 

140

 

 

185

 

 

636

 

 

922

Sofosbuvir / Velpatasvir(3) – Europe

 

 

66

 

 

69

 

 

292

 

 

299

Sofosbuvir / Velpatasvir(3) – Rest of World

 

 

71

 

 

75

 

 

344

 

 

374

 

 

 

276

 

 

330

 

 

1,272

 

 

1,596

 

 

 

 

 

 

 

 

 

Vemlidy – U.S.

 

 

149

 

 

148

 

 

507

 

 

486

Vemlidy – Europe

 

 

12

 

 

11

 

 

49

 

 

44

Vemlidy – Rest of World

 

 

125

 

 

100

 

 

514

 

 

428

 

 

 

287

 

 

260

 

 

1,070

 

 

959

 

 

 

 

 

 

 

 

 

Other Liver Disease(4) – U.S.

 

 

168

 

 

58

 

 

476

 

 

192

Other Liver Disease(4) – Europe

 

 

96

 

 

54

 

 

330

 

 

202

Other Liver Disease(4) – Rest of World

 

 

16

 

 

18

 

 

69

 

 

73

 

 

 

281

 

 

130

 

 

874

 

 

467

 

 

 

 

 

 

 

 

 

Total Liver Disease – U.S.

 

 

457

 

 

391

 

 

1,619

 

 

1,601

Total Liver Disease – Europe

 

 

174

 

 

134

 

 

671

 

 

545

Total Liver Disease – Rest of World

 

 

212

 

 

194

 

 

927

 

 

876

 

 

 

844

 

 

719

 

 

3,217

 

 

3,021

 

 

 

 

 

 

 

 

 

Veklury

 

 

 

 

 

 

 

 

Veklury – U.S.

 

 

80

 

 

108

 

 

470

 

 

892

Veklury – Europe

 

 

67

 

 

80

 

 

151

 

 

284

Veklury – Rest of World

 

 

65

 

 

150

 

 

290

 

 

623

 

 

 

212

 

 

337

 

 

911

 

 

1,799

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY – (Continued)

(unaudited)

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,

 

December 31,

(in millions)

 

 

2025

 

 

2024

 

 

2025

 

 

2024

Oncology

 

 

 

 

 

 

 

 

Cell Therapy

 

 

 

 

 

 

 

 

Tecartus – U.S.

 

 

32

 

 

53

 

 

153

 

 

234

Tecartus – Europe

 

 

51

 

 

36

 

 

158

 

 

138

Tecartus – Rest of World

 

 

7

 

 

10

 

 

32

 

 

31

 

 

 

90

 

 

98

 

 

344

 

 

403

 

 

 

 

 

 

 

 

 

Yescarta – U.S.

 

 

151

 

 

161

 

 

595

 

 

662

Yescarta – Europe

 

 

143

 

 

156

 

 

598

 

 

666

Yescarta – Rest of World

 

 

74

 

 

72

 

 

303

 

 

242

 

 

 

368

 

 

390

 

 

1,495

 

 

1,570

 

 

 

 

 

 

 

 

 

Total Cell Therapy – U.S.

 

 

183

 

 

213

 

 

748

 

 

896

Total Cell Therapy – Europe

 

 

193

 

 

193

 

 

755

 

 

804

Total Cell Therapy – Rest of World

 

 

82

 

 

82

 

 

335

 

 

274

 

 

 

458

 

 

488

 

 

1,839

 

 

1,973

Trodelvy

 

 

 

 

 

 

 

 

Trodelvy – U.S.

 

 

251

 

 

247

 

 

877

 

 

902

Trodelvy – Europe

 

 

88

 

 

77

 

 

347

 

 

294

Trodelvy – Rest of World

 

 

45

 

 

31

 

 

173

 

 

119

 

 

 

384

 

 

355

 

 

1,397

 

 

1,315

 

 

 

 

 

 

 

 

 

Total Oncology – U.S.

 

 

434

 

 

461

 

 

1,626

 

 

1,798

Total Oncology – Europe

 

 

281

 

 

269

 

 

1,102

 

 

1,098

Total Oncology – Rest of World

 

 

127

 

 

113

 

 

508

 

 

393

 

 

 

842

 

 

843

 

 

3,236

 

 

3,289

Other

 

 

 

 

 

 

 

 

AmBisome – U.S.

 

 

5

 

 

7

 

 

20

 

 

44

AmBisome – Europe

 

 

66

 

 

66

 

 

267

 

 

276

AmBisome – Rest of World

 

 

47

 

 

36

 

 

221

 

 

212

 

 

 

118

 

 

109

 

 

509

 

 

533

 

 

 

 

 

 

 

 

 

Other(5) – U.S.

 

 

52

 

 

51

 

 

177

 

 

255

Other(5) – Europe

 

 

9

 

 

8

 

 

32

 

 

34

Other(5) – Rest of World

 

 

26

 

 

16

 

 

81

 

 

68

 

 

 

87

 

 

76

 

 

290

 

 

356

 

 

 

 

 

 

 

 

 

Total Other – U.S.

 

 

57

 

 

59

 

 

197

 

 

299

Total Other – Europe

 

 

75

 

 

74

 

 

300

 

 

310

Total Other – Rest of World

 

 

72

 

 

52

 

 

302

 

 

280

 

 

 

205

 

 

184

 

 

799

 

 

889

 

 

 

 

 

 

 

 

 

Total product sales – U.S.

 

 

5,873

 

 

5,550

 

 

20,816

 

 

20,508

Total product sales – Europe

 

 

1,221

 

 

1,160

 

 

4,617

 

 

4,576

Total product sales – Rest of World

 

 

808

 

 

826

 

 

3,483

 

 

3,526

 

 

$

7,903

 

$

7,536

 

$

28,915

 

$

28,610

 

 

 

(1)

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2)

Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo/Yeytuo.

(3)

Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4)

Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.

(5)

Includes Cayston, Jyseleca, Letairis and Zydelig.

 

Investors:

Jacquie Ross, CFA

[email protected]

 

Media:

Ashleigh Koss

[email protected]

 

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology AIDS Health Infectious Diseases Hospitals Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BRISBANE, Calif.–(BUSINESS WIRE)–
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Investor Contact

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Surgery Health Medical Devices Genetics

MEDIA:

Logo
Logo

Union Pacific Recognized as Industry Leader in Intermodal Service in 2025

Union Pacific Recognized as Industry Leader in Intermodal Service in 2025

OMAHA, Neb.–(BUSINESS WIRE)–Union Pacific has been rated North America’s best performing railroad for intermodal service in 2025 in the Intermodal Service Scorecard published by the Journal of Commerce.

“We put a high value on our customers and their feedback. It’s why this recognition is so meaningful, because it comes from the people and businesses we serve,” said Union Pacific Executive Vice President of Marketing and Sales Kenny Rocker. “Our customers have choices and we’re proud they trust Union Pacific to keep their supply chains moving.”

Union Pacific was ranked the best Class I railroad for performance in intermodal service in both the Journal of Commerce’s spring and fall surveys for 2025. In the latest survey, which covers the second half of 2025, the railroad received “good” or “very good” ratings from 80% of respondents. Customers gave high marks to Union Pacific’s terminal gate processes for both inbound and outbound containers and for equipment availability.

Demonstrating Union Pacific’s strong intermodal service performance, the railroad continued to expand and enhance its intermodal service last year with new offerings, including the opening of its new intermodal terminal in Kansas City, Kansas.

“Our intermodal service is the best in the industry, and it’s going to be even stronger through our merger with Norfolk Southern,” said Rocker. “Not only is single-line cross-country service a game changer for enhanced reliability and lowering costs, but customers will also have one point of contact and one invoice.”

Union Pacific’s intermodal network reaches more markets, more frequently than any other North American railroad. The railroad’s 32,000 miles of track provide access to intermodal ramps in growing population centers across the western United States.

In August 2025, Union Pacific announced a new domestic intermodal service product, connecting the City of Industry in Southern California to the new terminal in Kansas City. Also, during that same month, Union Pacific introduced a new, truck-competitive domestic intermodal service connecting Southern California’s Inland Empire to Chicago, significantly boosting its intermodal capacity.

In September 2025, Union Pacific and Norfolk Southern announced a new domestic intermodal service connecting Union Pacific customers in western and southern markets with Norfolk Southern’s modernized intermodal facilities in the Louisville area.

ABOUT UNION PACIFIC

Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at www.up.com.

Union Pacific Media Contact: Robynn Tysver at 402-544-6037 or [email protected]

www.up.com

www.facebook.com/unionpacific

www.twitter.com/unionpacific

KEYWORDS: United States North America Nebraska

INDUSTRY KEYWORDS: Rail Transport Other Transport

MEDIA:

Logo
Logo